{"paper_id":"22c79772-028b-45b4-863f-b2b26b867136","body_text":"Population-Specific Biomarker Signatures in Alcohol... | F1000Research <!-- --> <!-- --> <!-- This is commented out to fix display problems on mobile devices. We may use it again once we implement a responsive design that supports native device resolutions. --> \"use strict\";function _typeof(t){return(_typeof=\"function\"==typeof Symbol&&\"symbol\"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&\"function\"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?\"symbol\":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement(\"iframe\");r.style.cssText=\"display:none\",r.name=\"__tcfapiLocator\",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&\"boolean\"==typeof n[3]&&(e=n[3],\"function\"==typeof n[2]&&n[2](\"set\",!0)):\"ping\"===n[0]?\"function\"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:\"stub\"}):o.push(n)},n.addEventListener(\"message\",(function(t){var e=\"string\"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n=\"object\"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,\"*\")}),n.parameter)}),!1))};\"undefined\"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:[\"bam.nr-data.net\"]}}; ;NREUM.loader_config={accountID:\"438030\",trustKey:\"438030\",agentID:\"772317073\",licenseKey:\"97f8f67f26\",applicationID:\"772317073\"} ;NREUM.info={beacon:\"bam.nr-data.net\",errorBeacon:\"bam.nr-data.net\",licenseKey:\"97f8f67f26\",applicationID:\"772317073\",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{\"use strict\";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error(\"All info objects require an agent identifier!\");if(!a[e])throw new Error(\"Info for \".concat(e,\" was never set\"));return a[e]}function c(e,t){if(!e)throw new Error(\"All info objects require an agent identifier!\");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],\"info\")}var u=r(7056);const d=()=>{const e={blockSelector:\"[data-nr-block]\",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:\"*\",maskAllInputs:!0,get blockClass(){return\"nr-block\"},get ignoreClass(){return\"nr-ignore\"},get maskTextClass(){return\"nr-mask\"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=\",\".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error(\"All configuration objects require an agent identifier!\");if(!f[e])throw new Error(\"Configuration for \".concat(e,\" was never set\"));return f[e]}function h(e,t){if(!e)throw new Error(\"All configuration objects require an agent identifier!\");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],\"config\")}function g(e,t){if(!e)throw new Error(\"All configuration objects require an agent identifier!\");var r=l(e);if(r){for(var n=t.split(\".\"),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||\"object\"!=typeof e)return(0,n.Z)(\"Setting a Configurable requires an object as input\");if(!t||\"object\"!=typeof t)return(0,n.Z)(\"Setting a Configurable requires a model to set its initial properties\");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{\"object\"==typeof e[a]&&\"object\"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)(\"An error occurred while setting a property of a Configurable\",e)}return r}catch(e){(0,n.Z)(\"An error occured while setting a Configurable\",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n=\"1.236.0\",i=\"PROD\",o=\"CDN\"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n=\"undefined\"!=typeof window&&!!window.document,i=\"undefined\"!=typeof WorkerGlobalScope&&(\"undefined\"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||\"undefined\"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:\"undefined\"!=typeof WorkerGlobalScope&&(\"undefined\"!=typeof self&&self instanceof WorkerGlobalScope&&self||\"undefined\"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=\"\"+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&\"undefined\"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\\s](\\d+\\.\\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:\"\",ee:void 0};class o{constructor(e){try{if(\"object\"!=typeof e)return(0,n.Z)(\"shared context requires an object as input\");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)(\"An error occured while setting SharedContext\",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:\"\",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:\"feature\";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s=\"nr@context\";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&\"object\"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;f<d;f++)s[f].apply(a,r);var l=T()[c[e]];return l&&l.push([p,e,r,a]),a}}function b(e,t){n[e]=w(e).concat(t)}function y(e,t){var r=n[e];if(r)for(var i=0;i {r.d(t,{E:()=>n,p:()=>i});var n=r(2177).ee.get(\"handle\");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o=\"feature\"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener(\"test\",null,e),n._A.removeEventListener(\"test\",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i=\"xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx\";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split(\"\").map((e=>\"x\"===e?o(t,++r).toString(16):\"y\"===e?(3&o()|8).toString(16):e)).join(\"\")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n=\"NRBA\",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||\"\").indexOf(\"data:\"))return{protocol:\"data\"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement(\"a\"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split(\"://\");!o.port&&a[1]&&(o.port=a[1].split(\"/\")[0].split(\"@\").pop().split(\":\")[1]),o.port&&\"0\"!==o.port||(o.port=\"https\"===a[0]?\"443\":\"80\"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],\"/\"!==o.pathname.charAt(0)&&(o.pathname=\"/\"+o.pathname);var s=!t.protocol||\":\"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),\"/\"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){\"function\"==typeof console.warn&&(console.warn(\"New Relic: \".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&\"object\"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)(\"feat-\"+t,[],void 0,e,r):(0,i.p)(\"block-\"+t,[],void 0,e,r),(0,i.p)(\"rumresp-\"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)(\"feat-\"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)(\"rumresp-\"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if(\"object\"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit(\"internal-error\",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return\"undefined\"==typeof document||\"complete\"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)(\"load\",e,t)}function a(e){if(i())return e();(0,n.iz)(\"DOMContentLoaded\",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:\"bam.nr-data.net\",errorBeacon:\"bam.nr-data.net\"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)(\"visibilitychange\",(function(){if(t)return void(\"hidden\"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i=\"nr@original\";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n=\"\");var a,s,c,u=\"-\"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,\"fetch\",y),t.on(y+\"end\",(function(e,r){var n=this;if(r){var i=r.headers.get(\"content-length\");null!==i&&(n.rxSize=i),t.emit(y+\"done\",[null,r],n)}else t.emit(y+\"done\",[e],n)})),t}const O={},j=[\"pushState\",\"replaceState\"];function S(e){const t=function(e){return(e||n.ee).get(\"history\")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,\"-\")),t}var P=r(3239);const C={},R=[\"appendChild\",\"insertBefore\",\"replaceChild\"];function I(e){const t=function(e){return(e||n.ee).get(\"jsonp\")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\\.([^.]+)/,a=/^(\\w+)(\\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,\"dom-\"),t.on(\"dom-start\",(function(e){!function(e){if(!e||\"string\"!=typeof e.nodeName||\"script\"!==e.nodeName.toLowerCase())return;if(\"function\"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if(\"function\"!=typeof u.parent[u.key])return;var d={};function f(){t.emit(\"jsonp-end\",[],d),e.removeEventListener(\"load\",f,(0,P.m$)(!1)),e.removeEventListener(\"error\",l,(0,P.m$)(!1))}function l(){t.emit(\"jsonp-error\",[],d),t.emit(\"jsonp-end\",[],d),e.removeEventListener(\"load\",f,(0,P.m$)(!1)),e.removeEventListener(\"error\",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],\"cb-\",d),e.addEventListener(\"load\",f,(0,P.m$)(!1)),e.addEventListener(\"error\",l,(0,P.m$)(!1)),t.emit(\"new-jsonp\",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get(\"mutation\")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,\"fn-\")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get(\"promise\")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,\"executor-\",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,\"name\",{value:\"Promise\"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),[\"all\",\"race\"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a(\"all\"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit(\"propagate\",[null,!i],o,!1,!1),i=i||!e}}}})),[\"resolve\",\"reject\"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit(\"propagate\",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,[\"onreadystatechange\"],\"fn-\",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit(\"xhr-resolved\",[],e)),i.inPlace(e,f,\"fn-\",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,\"-xhr-\",E),r.on(\"send-xhr-start\",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on(\"open-xhr-start\",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on(\"fn-end\",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i=\"nr@seenError\"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i=\"sm\",o=\"cm\",a=\"storeSupportabilityMetrics\",s=\"storeEventMetrics\"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i=\"firstbyte\",o=\"domcontent\",a=\"windowload\"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i=\"bstResource\",o=\"resource\",a=\"-start\",s=\"-end\",c=\"fn\"+a,u=\"fn\"+s,d=\"pushState\"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=[\"click\",\"submit\",\"keypress\",\"keydown\",\"keyup\",\"change\"],a=999,s=\"fn-start\",c=\"fn-end\",u=\"cb-start\",d=\"api-ixn-\",f=\"remaining\",l=\"interaction\",h=\"spaNode\",g=\"jsonpNode\",p=\"fetch-start\",m=\"fetch-done\",v=\"fetch-body-\",b=\"jsonp-end\",y=n.Yu.ST,w=\"-start\",x=\"-end\",A=\"-body\",E=\"cb\"+x,T=\"jsTime\",_=\"fetch\"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();[\"setErrorHandler\",\"finished\",\"addToTrace\",\"inlineHit\",\"addRelease\",\"addPageAction\",\"setCurrentRouteName\",\"setPageViewName\",\"setCustomAttribute\",\"interaction\",\"noticeError\",\"setUserId\"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,\"api\");const h={};var g=a.ee.get(e),p=g.get(\"tracer\"),m=\"api-\",v=m+\"ixn-\";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?\"session\":void 0)(t,r)}function y(){}[\"setErrorHandler\",\"finished\",\"addToTrace\",\"inlineHit\",\"addRelease\"].forEach((e=>h[e]=x(m,e,!0,\"api\"))),h.addPageAction=x(m,\"addPageAction\",!0,n.D.pageAction),h.setCurrentRouteName=x(m,\"routeName\",!0,n.D.spa),h.setPageViewName=function(t,r){if(\"string\"==typeof t)return\"/\"!==t.charAt(0)&&(t=\"/\"+t),(0,i.OP)(e).customTransaction=(r||\"http://custom.transaction\")+t,x(m,\"setPageViewName\",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if(\"string\"==typeof e){if([\"string\",\"number\"].includes(typeof t)||null===t)return b(e,t,\"setCustomAttribute\",r);(0,f.Z)(\"Failed to execute setCustomAttribute.\\nNon-null value must be a string or number type, but a type of was provided.\"))}else(0,f.Z)(\"Failed to execute setCustomAttribute.\\nName must be a string type, but a type of was provided.\"))},h.setUserId=function(e){if(\"string\"==typeof e||null===e)return b(\"enduser.id\",e,\"setUserId\",!0);(0,f.Z)(\"Failed to execute setUserId.\\nNon-null value must be a string type, but a type of was provided.\"))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a=\"function\"==typeof t;return(0,o.p)(v+\"tracer\",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?\"\":\"no-\")+\"fn-start\",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit(\"fn-err\",[arguments,this,\"string\"==typeof e?new Error(e):e],r),e}finally{p.emit(\"fn-end\",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,[\"API/\"+t+\"/called\"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,\"api\")})).catch((()=>(0,f.Z)(\"Downloading runtime APIs failed...\")))}return[\"actionText\",\"setName\",\"setAttribute\",\"save\",\"ignore\",\"onEnd\",\"getContext\",\"end\",\"get\"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){\"string\"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,[\"API/noticeError/called\"],void 0,n.D.metrics,g),(0,o.p)(\"err\",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,\"api\"),(0,h.Qy)(e,A,\"exposed\"),(0,h.EZ)(\"activatedFeatures\",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:\"ajax\",jserrors:\"jserrors\",metrics:\"metrics\",pageAction:\"page_action\",pageViewEvent:\"page_view_event\",pageViewTiming:\"page_view_timing\",sessionReplay:\"session_replay\",sessionTrace:\"session_trace\",spa:\"spa\"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:\"page_action-aggregate\",147:\"metrics-aggregate\",242:\"session-manager\",317:\"jserrors-aggregate\",348:\"page_view_timing-aggregate\",412:\"lazy-feature-loader\",439:\"async-api\",538:\"recorder\",590:\"session_replay-aggregate\",675:\"compressor\",733:\"session_trace-aggregate\",786:\"page_view_event-aggregate\",873:\"spa-aggregate\",898:\"ajax-aggregate\"}[e]||e)+\".\"+{78:\"ac76d497\",147:\"3dc53903\",148:\"1a20d5fe\",242:\"2a64278a\",317:\"49e41428\",348:\"bd6de33a\",412:\"2f55ce66\",439:\"30bd804e\",538:\"1b18459f\",590:\"cf0efb30\",675:\"ae9f91a8\",733:\"83105561\",786:\"06482edd\",860:\"03a8b7a5\",873:\"e6b09d52\",898:\"998ef92b\"}[e]+\"-1.236.0.min.js\"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t=\"NRBA:\",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName(\"script\"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:\"timeout\",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{\"undefined\"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:\"Module\"}),Object.defineProperty(e,\"__esModule\",{value:!0})},i.j=364,i.p=\"https://js-agent.newrelic.com/\",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&(\"load\"===r.type?\"missing\":r.type),a=r&&r.target&&r.target.src;s.message=\"Loading chunk \"+t+\" failed.\\n(\"+o+\": \"+a+\")\",s.name=\"ChunkLoadError\",s.type=o,s.request=a,n[1](s)}}),\"chunk-\"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,\"\".concat(e,\".enabled\"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,\"privacy.cookies_enabled\");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)(\"A problem occurred when starting up session manager. This page will not start or extend any session.\",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,\"aggregate\");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)(\"Downloading and initializing \".concat(this.featureName,\" failed...\"),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,\"session_trace.enabled\")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),(\"undefined\"==typeof PerformanceNavigationTiming||c.Tt)&&\"undefined\"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)(\"timing\",[\"load\",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if(\"count\"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r=\"\",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean(\"hidden\"===document.visibilityState),(0,N.N)((()=>(0,s.p)(\"docHidden\",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)(\"pagehide\",(()=>(0,s.p)(\"winPagehide\",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem(\"__nr_flags\").split(\",\"),console&&\"function\"==typeof console.log&&(L.console=!0,-1!==R.indexOf(\"dev\")&&(L.dev=!0),-1!==R.indexOf(\"nr_dev\")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on(\"internal-error\",(function(e){z(e.stack)})),L.dev&&H.ee.on(\"fn-err\",(function(e,t,r){z(r.stack)})),L.dev&&(z(\"NR AGENT IN DEVELOPMENT MODE\"),z(\"flags: \"+(0,b.D)(L,(function(e,t){return e})).join(\", \")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on(\"fn-start\",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on(\"fn-err\",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)(\"err\",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on(\"fn-end\",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on(\"internal-error\",(function(t){(0,s.p)(\"ierr\",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener(\"unhandledrejection\",(t=>{const r=function(e){let t=\"Unhandled Promise Rejection: \";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)(\"err\",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){\"function\"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)(\"err\",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)(\"ierr\",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||\"Uncaught error with no additional information\",this.sourceURL=t,this.line=r}let U=1;const q=\"nr@id\";function G(e){const t=typeof e;return!e||\"object\"!==t&&\"function\"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if(\"string\"==typeof e&&e.length)return e.length;if(\"object\"==typeof e){if(\"undefined\"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if(\"undefined\"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!(\"undefined\"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||\"\").toString()||null,i=(r.agentID||\"\").toString()||null,o=(r.trustKey||\"\").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return\"00-\"+t+\"-\"+e+\"-01\"}generateTraceContextStateHeader(e,t,r,n,i){return i+\"@nr=0-1-\"+r+\"-\"+n+\"-\"+e+\"----\"+t}generateTraceHeader(e,t,r,n,i,o){if(!(\"function\"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:\"Browser\",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,\"distributed_tracing\")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener(\"load\",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener(\"progress\",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader(\"X-NewRelic-ID\",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader(\"newrelic\",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader(\"traceparent\",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader(\"tracestate\",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{\"abort\"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),(\"load\"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||\"function\"!=typeof t.onload)&&\"function\"==typeof o.end)&&o.end(t)}catch(e){try{n.emit(\"internal-error\",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set(\"newrelic\",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set(\"traceparent\",t.traceContextParentHeader),t.traceContextStateHeader&&e.set(\"tracestate\",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;\"string\"==typeof i?r=i:\"object\"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&\"object\"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(\"\"+(i&&i instanceof Y&&i.method||n.method||\"GET\")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,\"string\"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i(\"xhr\",[this.params,o,this.startTime,this.endTime,\"fetch\"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||\"agent\")),this.start()):(0,l.Z)(\"Failed to initial the agent. Could not determine the runtime environment.\")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t=\"features\";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)(\"\".concat(t.featureName,\" is enabled but one or more dependent features has been disabled (\").concat((0,D.P)(n),\"). This may cause unintended consequences or missing data...\")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)(\"Failed to initialize all enabled instrument classes (agent aborted) -\",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)(\"bst\",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)(\"bstHist\",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get(\"tracer\"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get(\"events\"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit(\"newURL\",[\"\"+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,\"xhr-resolved\"],this.featureName),f.buffer([ve],this.featureName),u.buffer([\"setTimeout\"+le,\"clearTimeout\"+fe,ve],this.featureName),d.buffer([ve,\"new-xhr\",\"send-xhr\"+fe],this.featureName),l.buffer([me+fe,me+\"-done\",me+he+fe,me+he+le],this.featureName),h.buffer([\"newURL\"],this.featureName),g.buffer([ve],this.featureName),s.buffer([\"propagate\",be,ge,\"executor-err\",\"resolve\"+fe],this.featureName),o.buffer([ve,\"no-\"+ve],this.featureName),a.buffer([\"new-jsonp\",\"cb-start\",\"jsonp-error\",\"jsonp-end\"],this.featureName),y(l,me+fe),y(l,me+\"-done\"),y(a,\"new-jsonp\"),y(a,\"jsonp-end\"),y(a,\"cb-start\"),h.on(\"pushState-end\",m),h.on(\"replaceState-end\",m),window.addEventListener(\"hashchange\",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener(\"load\",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener(\"popstate\",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:\"spa\"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is \"complete\" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event \"completion\" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', \"PixelInitialized\", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { \"@context\": \"https://schema.org\", \"@type\": \"ScholarlyArticle\", \"mainEntityOfPage\": { \"@type\": \"WebPage\", \"@id\": \"https://f1000research.com/articles/14-1449\" }, \"headline\": \"Population-Specific Biomarker Signatures in Alcohol Use Disorder: Ethnic and Viral Influences in a Central...\", \"datePublished\": \"2025-12-24T13:32:42\", \"dateModified\": \"2026-05-19T11:47:33\", \"author\": [ { \"@type\": \"Person\", \"name\": \"Natalya Tseomashko\" }, { \"@type\": \"Person\", \"name\": \"Timur Syunyakov\" }, { \"@type\": \"Person\", \"name\": \"Inara Khayredinova\" }, { \"@type\": \"Person\", \"name\": \"Uktam Tadjibaev\" }, { \"@type\": \"Person\", \"name\": \"Furkat Bahramov\" }, { \"@type\": \"Person\", \"name\": \"Zarifjon Ashurov\" } ], \"publisher\": { \"@type\": \"Organization\", \"name\": \"F1000Research\", \"logo\": { \"@type\": \"ImageObject\", \"url\": \"https://f1000research.com/img/AMP/F1000Research_image.png\", \"height\": 480, \"width\": 60 } }, \"image\": { \"@type\": \"ImageObject\", \"url\": \"https://f1000research.com/img/AMP/F1000Research_image.png\", \"height\": 1200, \"width\": 150 }, \"description\": \" Background This study examined biomarker signatures in men with alcohol use disorder (AUD) in Uzbekistan, with and without viral infections. Methods A cross-sectional study included 292 males with stage II AUD (virus-negative: n = 251; virus-positive: n = 41) and 49 alcohol-free controls. Clinical, hematological, and biochemical parameters were measured, and ROC analysis evaluated diagnostic performance. Results Virus-negative patients showed the clearest biomarker profile of alcohol dependence, with reduced glucose, creatinine, and urea, and elevated total protein, α-amylase, De Ritis ratio, and direct bilirubin. ROC analysis confirmed strong diagnostic value for AST (AUC = 0.951), FIB-4 (0.877), MAP (0.817), and creatinine (0.711). Leukocytes (AUC = 0.790) and lymphocytes (0.735) best differentiated viral status. Fibrosis risk in virus-positive patients was 1.5-fold higher, with splenomegaly in 7.3%. Mild thrombocytopenia, absence of granulocytopenia, and rare delirium (&lt;5.5%) distinguished this cohort from European groups, resembling East Asian patterns. Conclusions Liver enzymes, α-amylase, bilirubin, MCV, FIB-4, and MAP provide strong diagnostic value for AUD. Multimarker panels including leukocyte, lymphocyte, and creatinine levels support viral status differentiation. Findings emphasize population-specific biomarker signatures in Central Asians and the utility of multimarker strategies for personalized AUD management. \" } { \"@context\": \"http://schema.org\", \"@type\": \"BreadcrumbList\", \"itemListElement\": [ { \"@type\": \"ListItem\", \"position\": \"1\", \"item\": { \"@id\": \"https://f1000research.com/\", \"name\": \"Home\" } }, { \"@type\": \"ListItem\", \"position\": \"2\", \"item\": { \"@id\": \"https://f1000research.com/browse/articles\", \"name\": \"Browse\" } }, { \"@type\": \"ListItem\", \"position\": \"3\", \"item\": { \"@id\": \"https://f1000research.com/articles/14-1449/v1\", \"name\": \"Population-Specific Biomarker Signatures in Alcohol Use Disorder:...\" } } ] } Home Browse Population-Specific Biomarker Signatures in Alcohol Use Disorder:... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Tseomashko N, Syunyakov T, Khayredinova I et al. Population-Specific Biomarker Signatures in Alcohol Use Disorder: Ethnic and Viral Influences in a Central Asian Cohort [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1449 ( https://doi.org/10.12688/f1000research.172858.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article Population-Specific Biomarker Signatures in Alcohol Use Disorder: Ethnic and Viral Influences in a Central Asian Cohort [version 1; peer review: 1 approved with reservations] Natalya Tseomashko https://orcid.org/0000-0001-6296-3409 1 , Timur Syunyakov 1-3 , Inara Khayredinova 1,4,5 , Uktam Tadjibaev 1 , Furkat Bahramov 1,5 , Zarifjon Ashurov 1,4,6 Natalya Tseomashko https://orcid.org/0000-0001-6296-3409 1 , Timur Syunyakov 1-3 , [...] Inara Khayredinova 1,4,5 , Uktam Tadjibaev 1 , Furkat Bahramov 1,5 , Zarifjon Ashurov 1,4,6 PUBLISHED 24 Dec 2025 Author details Author details 1 Republican Specialized Scientific and Practical Medical Center for Mental Health, Tashkent, Uzbekistan 2 International Centre for Education and Research in Neuropsychiatry (ICERN), Samara State Medical University,, Russia, Samara, Russian Federation 3 Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department, , Russia, Moscow, Russian Federation 4 Department of Psychiatry and Narcology of, Tashkent Medical Academy, Tashkent, Uzbekistan 5 Department of Narcology and Adolescent Psychopathology, of the Center for the Develop-ment of Professional Qualifications of Medical Workers, Tashkent, Uzbekistan 6 Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan Natalya Tseomashko Roles: Conceptualization, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing Timur Syunyakov Roles: Formal Analysis, Software, Supervision, Validation, Visualization, Writing – Review & Editing Inara Khayredinova Roles: Data Curation, Formal Analysis, Investigation, Writing – Original Draft Preparation Uktam Tadjibaev Roles: Data Curation, Investigation, Methodology Furkat Bahramov Roles: Data Curation, Investigation, Resources Zarifjon Ashurov Roles: Project Administration, Resources, Supervision OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Background This study examined biomarker signatures in men with alcohol use disorder (AUD) in Uzbekistan, with and without viral infections. Methods A cross-sectional study included 292 males with stage II AUD (virus-negative: n = 251; virus-positive: n = 41) and 49 alcohol-free controls. Clinical, hematological, and biochemical parameters were measured, and ROC analysis evaluated diagnostic performance. Results Virus-negative patients showed the clearest biomarker profile of alcohol dependence, with reduced glucose, creatinine, and urea, and elevated total protein, α-amylase, De Ritis ratio, and direct bilirubin. ROC analysis confirmed strong diagnostic value for AST (AUC = 0.951), FIB-4 (0.877), MAP (0.817), and creatinine (0.711). Leukocytes (AUC = 0.790) and lymphocytes (0.735) best differentiated viral status. Fibrosis risk in virus-positive patients was 1.5-fold higher, with splenomegaly in 7.3%. Mild thrombocytopenia, absence of granulocytopenia, and rare delirium (<5.5%) distinguished this cohort from European groups, resembling East Asian patterns. Conclusions Liver enzymes, α-amylase, bilirubin, MCV, FIB-4, and MAP provide strong diagnostic value for AUD. Multimarker panels including leukocyte, lymphocyte, and creatinine levels support viral status differentiation. Findings emphasize population-specific biomarker signatures in Central Asians and the utility of multimarker strategies for personalized AUD management. READ ALL READ LESS Keywords alcohol use disorder, viral infection, biomarkers, ROC analysis, liver enzymes, popula-tion-specific reference values Corresponding Author(s) Natalya Tseomashko ( [email protected] ) Close Corresponding author: Natalya Tseomashko Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2025 Tseomashko N et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Tseomashko N, Syunyakov T, Khayredinova I et al. Population-Specific Biomarker Signatures in Alcohol Use Disorder: Ethnic and Viral Influences in a Central Asian Cohort [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1449 ( https://doi.org/10.12688/f1000research.172858.1 ) First published: 24 Dec 2025, 14 :1449 ( https://doi.org/10.12688/f1000research.172858.1 ) Latest published: 19 May 2026, 14 :1449 ( https://doi.org/10.12688/f1000research.172858.2 )  There is a newer version of this article available. Suppress this message for one day. 1. Introduction Alcohol use disorder (AUD) is a serious public health problem with significant social, economic, and medical consequences, as it primarily affects individuals of working and reproductive age. Globally, 5.3% of deaths are attributable to alcohol consumption, and more than 2.4 million people suffer from alcohol-related cirrhosis. 1 Alcohol abuse damages multiple organs and systems, including the liver, pancreas, heart, kidneys, nervous system, and hematopoietic cells. 2 Reliable diagnostic and prognostic biomarkers provide a minimally invasive approach—most commonly blood-based—for early detection and management. The integration of biomarker screening with instrumental and clinical data forms the basis of modern diagnostics. Biomarker variability is strongly influenced by sex, age, ethnicity, and geography, 3 reflecting environmental and cultural factors such as diet, lifestyle, and alcohol consumption habits. Even closely related ethnic groups with distinct dietary patterns and attitudes toward psychoactive substances demonstrate significant biochemical differences. 4 These phenotypic traits are reinforced at the genetic level through diverse functional combinations of single nucleotide polymorphisms (SNPs), which regulate physiological and pathological processes. 5 This underscores the importance of population- and ethnicity-specific research. The present cross-sectional study assessed hematological and biochemical parameters in alcohol-dependent patients with and without viral infections in Uzbekistan, compared with healthy controls. 2. Materials and Methods 2.1 Study design and population A cross-sectional study was conducted at the Republican Specialized Scientific and Practical Medical Center for Mental Health (RSSPMCMH, Uzbekistan). To minimize readmissions, the enrollment period was restricted to 3 months, yielding 292 male patients with stage II alcohol use disorder (AUD) and 49 alcohol-free controls. Female patients (n = 8) and mild AUD cases (n = 2) were excluded. One control was excluded after hepatitis B detection. Final groups: Cohort 1 (AUD without viral infection, n = 251), Cohort 2 (AUD with hepatitis B, C, or HIV infection, n = 41), and Cohort 3 (controls, n = 49). 2.2 Inclusion/Exclusion criteria Inclusion: men aged 20–65 with ICD-10 F10.2 diagnosis of stage II chronic alcoholism. Controls: age-matched males without alcohol or psychoactive substance use, confirmed clinically and by laboratory tests. Exclusion: females, mild withdrawal symptoms, acute infections, and controls with previously undiagnosed viral infections. 2.3 Ethical approval The study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Local Ethics Committee of the Republican Specialized Scientific and Practical Medical Center for Mental Health (RSSPMCMH), Tashkent, Uzbekistan (Approval No. 1/2025, 18 March 2025). Written informed consent was obtained from all participants. 2.4 Data collection Somatic status was assessed by clinical examination and instrumental diagnostics. Hematological and biochemical parameters were measured using automated analyzers (Mindray, China) with standardized enzymatic and colorimetric methods (detailed description provided in Supplementary File S1 — Supplementary Methods). Composite indices included FIB-4, De Ritis ratio, mean arterial pressure (MAP), and body mass index (BMI), calculated by standard formulas. 2.5 ROC analysis Diagnostic accuracy of biomarkers was evaluated by ROC analysis. AUROC values with 95% confidence intervals were estimated using bootstrap resampling (n = 1000). Optimal cut-offs were determined by Youden’s Index, with corresponding sensitivity and specificity reported. 2.6 Statistical analysis Analyses were performed using Python 3.11 (scikit-learn, numpy, pandas, matplotlib). Nonparametric tests (Mann-Whitney U, Kruskal-Wallis H, χ 2 with Bonferroni correction) were applied; significance was set at p < 0.05. A retrospective power analysis confirmed ≥85% power for detecting medium-to-large effect sizes despite the smaller control group. 3. Results 3.1 Somatic and clinical profile of alcohol-dependent patients Among the 292 alcohol-dependent male patients examined, 14% (n = 41) were identified as carriers of viral infections, including hepatitis C (n = 18), hepatitis B (n = 18), combined hepatitis B and C (n = 1), triple hepatitis B/C/D (n = 1), HIV (n = 2), and HIV with hepatitis B (n = 1). Despite variation within groups, average age did not differ significantly across cohorts (see Table 1 ). Patients over 50 years old typically had alcohol use histories exceeding 10 years. Table 1. Clinical and anthropometric characteristics (age, BMI, FIB-4, MAP) in alcohol-dependent patients without viral infection (Cohort 1, n = 251), alcohol-dependent patients with viral infection (Cohort 2, n = 41), and healthy controls (Cohort 3, n = 49). Values are presented as medians (Q1–Q3) or n (%). Indicators Level Cohort 1 (n = 251) Cohort 2 (n = 41) Cohort 3 (n = 49) Test results AGE, Median, Q1, Q3 45.0 (38.0, 53.0) 44.0 (39.0, 48.0) 42.0 (36.0, 49.0) H(2) = 4.52, p = 0.104, ε 2 = 0.013 BMI, kg/m 2 , Median, Q1, Q3 24.0 (22.9, 25.0) 24.3 (23.4, 26.1) 27.1 (24.5, 28.6) H(2) = 27.13, p < 0.001, ε 2 = 0.080 BMI, kg/m 2 Qualitative, n (%) Above Norm 61 (24.30%) 16 (39.0%) 34 (69.4%) χ 2 (4) = 39.14, p < 0.001, V = 0.240 Below norm 7 (2.79%) 1 (2.44%) 0 (0.00%) Norm 183 (72.9%) 24 (58.5%) 15 (30.6%) FIB-4, POINTS Qualitative, n % Above Norm 67 (26.69%) 17 (41.5%) 0 (0.00%) χ 2 (2) = 22.84, p < 0.001, V = 0.259 Norm 184 (73.3%) 24 (58.5%) 49 (100%) МАР, mmHG, Median, Q1, Q3 103.0 (97.0, 103.0) 103.0 (97.0, 107.0) 93.0 (93.0, 97.0) H(2) = 56.17, p < 0.001, ε 2 = 0.165 МАР, mm HG Qualitative, n% Above Norm 18 (7.17%) 4 (9.76%) 2 (4.1%) χ 2 (2) = 1.12, p = 0.570,V = 0.057 Norm 233 (92.8%) 37 (90.2%) 47 (95.9%) Severe withdrawal symptoms were reported in 9% (n = 23) of patients, all from the virus-negative group, whereas only 1.15% (n = 3) of virus-positive individuals were affected. Most patients (85.5%) exhibited moderate withdrawal symptoms. The study population was predominantly Turkic-speaking (94.5%, n = 276), mainly of Uzbek ethnicity. Both alcohol-dependent patients (n = 292) and alcohol-free controls (n = 49) demonstrated comparable ethnic composition, ensuring cohort homogeneity. Notably, psychotic symptoms (delirium and/or hallucinations) were observed in 5.5% (n = 16) of alcohol-dependent patients. Among these, 43.8% (n = 7) were of Slavic origin and 18.8% (n = 3) were Tatar, despite these groups comprising only 6.1% and 2.7% of the total alcohol-dependent cohort, respectively. This disproportion suggests a potential ethnogenetic vulnerability to alcohol-related neuropsychiatric complications. Elevated FIB-4 scores (≥4) and MAP were more frequent among virus-positive patients, reflecting advanced fibrosis and vascular dysregulation. The prevalence of somatic comorbidities varied across study groups (see Figure 1 ). Figure 1. Prevalence of somatic comorbidities in alcohol-dependent patients without viral infection (Cohort 1, n = 251), with viral infection (Cohort 2, n = 41), and healthy controls (Cohort 3, n = 49). Hypertension, cardiopathy, chronic pancreatitis, cholecystitis, encephalopathy, splenomegaly, and cirrhosis are shown as relative frequencies (%). Hypertension was more frequent in alcohol-dependent patients (11.5% without viral infection; 12.2% with viral infection) compared to controls (8.2%) ( p < 0.05 for both patient groups vs. controls). Cardiopathy occurred in 21.9% of virus-positive patients and 16.3% of virus-negative patients versus 0% in controls (C vs. V, ** p < 0.001; C vs. N, ** p < 0.001). Chronic pancreatitis was observed in 31.7% of virus-positive and 23.0% of virus-negative patients compared to 0% in controls (C vs. V, ** p < 0.001; C vs. N, ** p < 0.001). Chronic cholecystitis was the most prevalent condition, affecting 75.6% of virus-positive and 67.5% of virus-negative patients versus 4.1% in controls (C vs. both patient groups, ** p < 0.001). Encephalopathy occurred in 7.3% of virus-positive and 9.2% of virus-negative patients, while it was absent in controls (C vs. V, * p < 0.05; not significant for C vs. N or V vs. N). Splenomegaly was found only in virus-positive patients (7.3%, p < 0.01). Cirrhosis was also observed exclusively in this group (4.9%), although differences did not reach statistical significance. No significant variation was identified for ischemic heart disease, hepatomegaly, or chronic pyelonephritis (all p > 0.05). 3.2 Hematological profile analysis A comparative analysis of hematological parameters was conducted among virus-positive (n = 41) and virus-negative (n = 251) alcohol-dependent patients, and an alcohol-free control group (n = 49). Only values outside physiological reference ranges were considered. Hematological parameters are summarized in Supplementary Table S1. Hemoglobin (Hb) levels were significantly reduced in both alcohol-dependent groups, falling below normal in 78% of virus-positive and 45% of virus-negative patients. Macrocytosis, defined as MCV > 100 fL, was observed in 17–29% of alcohol-dependent individuals versus 6.1% of controls (p < 0.001), supporting its association with chronic alcohol exposure. Erythrocyte sedimentation rate (ESR) was elevated in 63.4% of virus-positive and 57.4% of virus-negative patients (p < 0.001), compared to 10.2% of controls, indicating systemic inflammation, especially with viral comorbidity. Leukocytosis was more common in virus-positive patients (36.6%) than in virus-negative patients (15.1%). A right shift in the differential count—with increased segmented neutrophils showing nuclear hypersegmentation—was noted in 7.6–9.8% of patients, suggesting megaloblastic anemia or hepatic/renal impairment. Lymphocytosis, likely reflecting antiviral immune activation, was present in 9.2% of virus-positive and 5% of virus-negative individuals, while lymphocytopenia occurred in 16.3% of controls. Unexpectedly, monocytosis was more frequent in controls (44.9%) than in alcohol-dependent individuals (20–26.8%), possibly reflecting transient immune responses. Thrombocytopenia was identified in 13.5–17.1% of alcohol-dependent patients versus 4% of controls (p = 0.029). Mean platelet volume (MPV), a marker of platelet activation and turnover, was elevated in 41.5% of virus-positive patients, compared to 16.7–22.4% in the other groups (p < 0.001). 3.3 Biochemical profile analysis Biochemical parameters were evaluated in virus-positive (n = 41) and virus-negative (n = 251) alcohol-dependent patients, as well as in an alcohol-free control group (n = 49). Detailed biochemical characteristics across the three study cohorts are presented in Supplementary Table S2. As shown in Supplementary Table S2, glucose levels were slightly lower in alcohol-dependent groups compared to controls. However, within alcohol-dependent cohorts, virus-positive patients demonstrated 1.2-fold higher glucose levels than virus-negative individuals (p = 0.002), possibly reflecting altered gluconeogenesis and insulin sensitivity. Creatinine concentrations were reduced in both alcohol-dependent groups by ~1.5-fold vs. controls, likely indicating reduced muscle mass or altered renal tubular function. α-Amylase (AAMY) levels were significantly higher in alcohol-dependent patients, with mean values 1.7 times those of controls (p < 0.001; Dunn’s test; r = 0.01). However, elevated enzyme activity was found in only 2.4–8.2% of individuals. This likely reflects total α-amylase activity, not limited to pancreatic isoforms, which is common in chronic alcohol users. Liver enzymes showed marked alterations. ALT levels were 2.1 times higher in both alcohol-dependent cohorts versus controls (p < 0.001), and 1.2 times higher in virus-positive vs. virus-negative patients—suggesting additive liver injury from viral and alcohol-related mechanisms. AST levels were approximately threefold higher in alcohol-dependent groups, with slightly greater elevation in the virus-negative cohort, possibly due to dominant alcohol-related damage. Bilirubin profiles varied: conjugated bilirubin was elevated in 72% of virus-negative and 65.9% of virus-positive patients. However, virus-positive individuals also demonstrated elevated unconjugated bilirubin, implying compromised hepatic conjugation capacity. Thus, according to the obtained data, statistically significant differences (p < 0.001) in blood biomarker profiles between alcohol-dependent patients and individuals without alcohol abuse (control cohort) were observed among biochemical markers, specifically liver enzymes (ALT, AST), bilirubin fractions, creatinine, glucose, and urea, while among hematological indicators, the most pronounced distinctions were noted for hemoglobin, erythrocyte sedimentation rate, and mean corpuscular volume of erythrocytes. Detailed distributions of biochemical biomarkers across the three cohorts are shown in Supplementary Figure S1. 3.4 Diagnostic accuracy analysis (ROC) To evaluate the diagnostic potential of clinical and laboratory markers, Receiver Operating Characteristic (ROC) analysis was performed (see Table 2 ). Table 2. Diagnostic accuracy of biochemical and hematological biomarkers in differentiating (a) alcohol-dependent patients (Cohorts 1+2) vs. controls (Cohort 3) and (b) AUD without viral infection (Cohort 1) vs. AUD with viral infection (Cohort 2). Class coding: (a) Positive = Cohorts 1+2, Negative = Cohort 3; (b) Positive = Cohort 2, Negative = Cohort 1. Indicator Comparison Dir. AUROC (95% CI) Threshold Se (%) Sp (%) AAMY Cohort 3 vs Cohorts 1+2 ↑ 0.802 (0.736–0.867) 73.00 70.0 80.0 Cohort 1 vs Cohort 2 ↑ 0.556 (0.459–0.653) 57.00 78.0 38.0 ALT Cohort 3 vs Cohorts 1+2 ↑ 0.808 (0.743–0.873) 52.00 79.0 71.0 Cohort 1 vs Cohort 2 ↑ 0.567 (0.469–0.664) 59.20 49.0 69.0 AST Cohort 3 vs Cohorts 1+2 ↑ 0.951 (0.915–0.987) 73.00 94.0 89.0 Cohort 1 vs Cohort 2 ↑ 0.514 (0.418–0.610) 149.70 22.0 88.0 Bilirubin, direct Cohort 3 vs Cohorts 1+2 ↑ 0.799 (0.727–0.870) 3.10 90.1 61.2 Cohort 1 vs Cohort 2 ↓ 0.451 (0.359–0.544) 22.30 15.0 89.0 Bilirubin, total Cohort 3 vs Cohorts 1+2 ↑ 0.730 (0.664–0.796) 24.20 52.0 92.0 Cohort 1 vs Cohort 2 ↑ 0.536 (0.441–0.631) 21.90 68.0 45.0 Creatinine Cohort 3 vs Cohorts 1+2 ↓ 0.060 (0.000–0.123) 203.40 0.0 100. Cohort 1 vs Cohort 2 ↑ 0.711 (0.633–0.789) 75.00 88.0 46.0 AST/ALT Cohort 3 vs Cohorts 1+2 ↑ 0.773 (0.701–0.845) 1.75 81.0 74.0 Cohort 1 vs Cohort 2 ↓ 0.461 (0.364–0.559) 2.15 32.0 72.0 Glucose Cohort 3 vs Cohorts 1+2 ↓ 0.242 (0.181–0.300) 19.90 0.0 100. Cohort 1 vs Cohort 2 ↑ 0.663 (0.567–0.759) 4.40 66.0 67.0 Total protein Cohort 3 vs Cohorts 1+2 ↑ 0.620 (0.495–0.745) 68.00 86.3 61.2 Cohort 1 vs Cohort 2 ↑ 0.528 (0.431–0.624) 77.00 44.0 66.0 Urea Cohort 3 vs Cohorts 1+2 ↓ 0.291 (0.205–0.377) 2.07 100.0 2.1 Cohort 1 vs Cohort 2 ↓ 0.437 (0.345–0.528) 3.89 85.0 25.0 BMI Cohort 3 vs Cohorts 1+2 ↓ 0.276 (0.189–0.362) 45.60 0.0 100. Cohort 1 vs Cohort 2 ↑ 0.555 (0.458–0.653) 25.10 39.0 75.0 FIB-4 Cohort 3 vs Cohorts 1+2 ↑ 0.877 (0.820–0.935) 1.16 76.0 96.0 Cohort 1 vs Cohort 2 ↑ 0.525 (0.399–0.651) 0.90 92.0 19.0 MAP Cohort 3 vs Cohorts 1+2 ↑ 0.817 (0.730–0.904) 97.00 96.0 59.0 Cohort 1 vs Cohort 2 ↑ 0.550 (0.453–0.647) 107.00 29.0 80.0 Hb Cohort 3 vs Cohorts 1+2 ↓ 0.310 (0.240–0.380) 108.00 99.0 6.0 Cohort 1 vs Cohort 2 ↓ 0.260 (0.173–0.346) 109.00 100.0 2.0 MCV Cohort 3 vs Cohorts 1+2 ↑ 0.710 (0.635–0.785) 89.30 74.0 62.0 Cohort 1 vs Cohort 2 ↑ 0.513 (0.430–0.596) 89.30 88.0 28.0 PLT Cohort 3 vs Cohorts 1+2 ↑ 0.520 (0.446–0.594) 230.00 51.0 63.3 Cohort 1 vs Cohort 2 ↓ 0.377 (0.291–0.463) 347.00 5.0 96.0 MPV Cohort 3 vs Cohorts 1+2 ↑ 0.522 (0.432–0.612) 10.10 77.1 34.7 Cohort 1 vs Cohort 2 ↑ 0.539 (0.442–0.636) 11.20 41.0 85.0 Monocytes Cohort 3 vs Cohorts 1+2 ↓ 0.409 (0.315–0.502) 16.60 1.4 100. Cohort 1 vs Cohort 2 ↑ 0.682 (0.587–0.777) 9.50 98.0 37.0 Lymphocyte Cohort 3 vs Cohorts 1+2 ↑ 0.585 (0.490–0.681) 28.80 75.0 46.9 Cohort 1 vs Cohort 2 ↑ 0.735 (0.643–0.826) 33.90 90.0 64.0 NEUT Cohort 3 vs Cohorts 1+2 ↑ 0.510 (0.423–0.598) 66.00 26.7 81.6 Cohort 1 vs Cohort 2 ↑ 0.577 (0.480–0.675) 66.40 41.0 79.0 WBC Cohort 3 vs Cohorts 1+2 ↑ 0.680 (0.601–0.759) 7.21 55.1 77.6 Cohort 1 vs Cohort 2 ↑ 0.790 (0.705–0.876) 7.50 95.0 59.0 Two comparisons were made: (а) Cohort 3 (controls) vs. Cohorts 1+2 (all alcohol-dependent patients); (b) Cohort 1 (virus-negative) vs. Cohort 2 (virus-positive alcohol-dependent patients). The area under the curve (AUC) quantifies discrimination ability (1.0 = perfect). Sensitivity and specificity reflect correct identification of true positives and true negatives. Key findings (Cohorts 1+2 vs. controls): AST: AUC = 0.951 (95% CI: 0.915–0.987), 94% sensitivity, 89% specificity at 73 U/L; FIB-4: AUC = 0.877 (95% CI: 0.820–0.935), 76% sensitivity, 96% specificity at 1.16; MAP: AUC = 0.817, 96% sensitivity, 59% specificity at 97 mmHg; ALT: AUC = 0.808; AAMY = 0.802; direct bilirubin = 0.799; Poor discriminators: BMI (0.276), Creatinine (0.060). Key findings (virus-negative vs. virus-positive): WBC: AUC = 0.790 (95% CI: 0.705–0.876), 95% sensitivity, 59% specificity; Lymphocytes: AUC = 0.735, 90% sensitivity, 64% specificity; Monocytes: AUC = 0.682, 98% sensitivity, 37% specificity; Creatinine: AUC = 0.711, 88% sensitivity, 46% specificity. 4. Discussion This study investigated biochemical, hematological, and somatic characteristics in two alcohol-dependent cohorts—with and without viral infections—compared to controls. Statistically significant differences were observed across multiple parameters, underscoring the impact of chronic alcohol use and viral coinfection on systemic physiology. Although the relatively small control group is a limitation, post hoc power analysis for key markers such as ALT indicated sufficient statistical power (≥85%), supporting the robustness of the findings. Non-invasive indices including BMI, MAP, and the FIB-4 score were employed to assess metabolic and hepatic status. The FIB-4 index identified fibrotic changes in 42% of patients with viral infections and in 27% of virus-negative alcohol-dependent individuals, consistent with long-term alcohol exposure and previously reported fibrosis rates. 6 Our results demonstrate a substantial burden of somatic complications in alcohol-dependent men, with notable differences between those with and without viral comorbidity. The high prevalence of chronic cholecystitis and pancreatitis highlights cumulative hepatopancreatic injury, amplified in virus-positive patients. Cardiopathy was disproportionately common in virus-positive patients, supporting the notion that viral infection aggravates cardiovascular vulnerability. Splenomegaly was observed exclusively in virus-positive individuals (7.3%), suggesting greater risk of portal hypertension and advanced hepatic involvement. Cirrhosis was also detected only in virus-positive patients, though without statistical significance, likely reflecting sample size limitations rather than absence of association. Encephalopathy occurred in both patient cohorts but was absent in controls, suggesting it is primarily linked to alcohol exposure rather than viral status. The lack of difference between groups supports AUD as the principal driver of neurotoxic complications. 7 In contrast, ischemic heart disease, hepatomegaly, and chronic pyelonephritis showed no significant differences, implying closer relation to lifestyle or cumulative alcohol exposure than to viral comorbidity. Significant reductions in hemoglobin (Hb) were detected in both alcohol-dependent cohorts, with subnormal levels in 75% of virus-positive and 50% of virus-negative individuals. Ethanol and acetaldehyde exert cytotoxic effects on erythroid precursors and promote oxidative stress. 8 Individuals with reduced aldehyde dehydrogenase (ALDH2) activity—common in Asian populations—accumulate more acetaldehyde, leading to enhanced hemoglobin-acetaldehyde adduct (HbAA) formation. 9 This mechanism may partly explain higher susceptibility to liver injury and anemia in Asian alcohol users. Our data are consistent with Russian findings showing reduced hemoglobin in alcohol-dependent individuals, although baseline values in the Russian cohort were higher, potentially due to ethnic-genetic or environmental differences. 10 Inflammatory markers including ESR, leukocyte count, and lymphocytes were elevated in alcohol-dependent groups, particularly in those with viral coinfection, suggesting ongoing systemic inflammation. Increases in Candida albicans-specific Th17 cells, as reported by Zeng et al., may reflect fungal colonization and immune activation in alcohol-associated liver disease. 11 Unexpectedly, monocytosis was more frequent in controls, possibly reflecting immune responses to non-viral stimuli. Chronic alcohol use induces both immune suppression and hyperinflammation through epigenetic alterations of monocyte/macrophage function. 8 Despite this, granulocytopenia was rare and comparable between groups, differing from some prior studies. 12 Thrombocytopenia was also confirmed, with significantly lower platelet counts (PLT) in alcohol-dependent patients. While low PLT has been associated with withdrawal-related neuropsychiatric complications, 13 no such manifestations were observed in patients with severe thrombocytopenia here. Interestingly, platelet counts were near normal in individuals with delirium or hallucinations, suggesting thrombocytopenia may not be the primary driver of these symptoms. The mean platelet volume (MPV), an indicator of platelet activation, was elevated in 41.5% of virus-positive patients, reflecting increased turnover or stress-induced megakaryopoiesis, potentially mediated by acetaldehyde toxicity and ALDH2 variants. 14 , 15 Our findings on macrocytosis are consistent with prior studies. MCV was elevated in up to 29% of alcohol-dependent patients, supporting its role as a biomarker of chronic alcohol exposure. 16 – 18 Mechanistically, macrocytosis may reflect direct erythrocyte toxicity or deficiencies in folate, vitamin B12, and liver function. 19 Serum α-amylase was significantly higher in alcohol-dependent patients than in controls, despite overall lower activity than reported in Brazilian studies. 20 Elevated amylase may reflect pancreatic/hepatic inflammation 21 or sympathetic activation, as suggested by King and Nater. 22 , 23 The AST/ALT ratio (De Ritis index) followed expected patterns, being higher in alcohol-dependent individuals and slightly more elevated in those without viral infections, consistent with alcoholic liver disease and corroborated by Iluz-Freundlich et al. 24 Elevated direct bilirubin further supported cholestasis. In contrast, unconjugated hyperbilirubinemia was more frequent in virus-positive individuals, suggesting impaired conjugation and hepatocellular function. Elevated bilirubin in 19–24% of controls may reflect subclinical liver dysfunction, possibly driven by poor diet and sedentary lifestyle. Similar trends were documented in Indian and Chinese populations. 25 , 26 Creatinine was significantly lower in alcohol-dependent individuals, consistent with prior reports, 27 possibly reflecting reduced muscle mass or impaired renal function. These findings support including creatinine in the MELD score, a validated mortality predictor in end-stage liver disease. 28 Glucose and total protein showed paradoxical trends: hyperglycemia and hypoproteinemia were more common in controls, possibly due to obesity. In contrast, elevated globulin fractions in alcohol-dependent individuals may reflect chronic inflammation. 29 , 30 Hypoglycemia was present in 27.1% of virus-negative alcohol-dependent patients, consistent with alcoholic ketoacidosis. This warrants expanded biochemical assessment in future studies, including ketone body and osmolality measurements. 31 – 34 Neuropsychiatric symptoms (e.g., delirium, hallucinations) were present in 5.5% of alcohol-dependent patients. Strikingly, 36.8% of Slavic individuals in the alcohol group exhibited such symptoms, despite representing only 6.1% of the cohort. These observations may reflect population-specific genetic differences in enzymatic systems involved in alcohol metabolism. 10 Finally, ROC analysis highlights the effectiveness of liver-specific biomarkers (AST, ALT, FIB-4) and systemic parameters (MAP, AAMY) in distinguishing alcohol-dependent patients from controls. Elevated AUC values for AST and FIB-4 align with prior research indicating hepatic injury and fibrotic transformation. 35 , 36 MAP elevation is consistent with alcohol-induced sympathetic activation. 37 In subgroup analysis, immune-inflammatory markers (WBC, lymphocytes, monocytes) were more relevant for differentiating virus-positive from virus-negative patients, suggesting viral coinfection contributes additional immunologic changes. 38 , 39 The findings reinforce the utility of combining biochemical, hematological, and physiological markers to enhance diagnostic accuracy. However, the low efficiency of some markers (e.g. platelets, hemoglobin, BMI) suggests their limited role and is most likely due to ethnopopulation characteristics. This study has several limitations. First, only male patients were included, as the small number of female participants and sex-related biomarker variability precluded meaningful subgroup analysis. Second, the recruitment period was restricted to 3 months to minimize patient recirculation and ensure the dataset reflected primary screening; while methodologically justified, this limited the overall sample size. Third, the control group was relatively small compared to the patient cohorts. Despite these limitations, the study provides novel and valuable population-specific insights into biomarker profiles in alcohol use disorder with and without viral comorbidity. Importantly, this work represents the first systematic investigation of such biomarkers in a poorly studied population of alcohol-dependent individuals in Uzbekistan, highlighting the need for further research in this unique setting. 5. Conclusion ROC analysis confirmed the strong diagnostic value of liver enzymes (AST, ALT), α-amylase, MCV, direct bilirubin, the De Ritis ratio, FIB-4 index, and mean arterial pressure (MAP) in identifying alcohol dependence. Leukocyte, lymphocyte, and creatinine levels were the most informative for distinguishing patients with viral comorbidity. These findings highlight the clinical utility of multimarker panels for early detection, differentiation, and risk stratification in alcohol use disorder. Importantly, deviations between Uzbek control values and international reference ranges underline the need for population- and ethnicity-specific interpretation of biochemical and hematological markers in clinical practice. Establishing regionally validated diagnostic thresholds could improve accuracy of screening and personalized management of patients with alcohol use disorder in Central Asia. Declaration of generative AI and AI-assisted technologies The authors used ChatGPT (OpenAI, 2025) to improve the language. After using this tool, the authors reviewed and edited the content and take full responsibility for the publication’s content. Data availability Underlying data Repository: Population-Specific Biomarker Dataset for Alcohol Use Disorder in Uzbekistan. DOI: https://doi.org/10.5281/zenodo.17673836 40 The project contains the following underlying data: Raw Dataset – Hematology_Biochemistry_Somatic.xlsx (raw anonymized patient-level hematological, biochemical, somatic, and clinical data for all three cohorts). Extended data Repository: Population-Specific Biomarker Dataset for Alcohol Use Disorder in Uzbekistan. DOI: https://doi.org/10.5281/zenodo.17673836 40 This project contains the following extended data: - Supplementary File S1 — Supplementary Methods (detailed description of laboratory methods, formulas for derived indices, and ROC analysis procedures). - Supplementary Table S1 – Hematological biomarkers (group-level distributions and statistical comparisons of hematological parameters across cohorts). - Supplementary Table S2 – Biochemical biomarkers (group-level distributions and statistical comparisons of biochemical parameters across cohorts). - Supplementary Figure S1 – Box plot distributions of biochemical biomarkers in the study cohorts. Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC BY 4.0). Acknowledgments The work was carried out in accordance with the research plan for the current year and approved by the Ministry of Health of the Republic of Uzbekistan. The work was carried out on the basis of the Republican Specialized Scientific and Practical Medical Center for Mental Health. References 1. Aslam A, Kwo PY: Epidemiology and disease burden of alcohol-associated liver disease. J. Clin. Exp. Hepatol. 2023; 13 (1): 88–102. PubMed Abstract | Publisher Full Text | Free Full Text 2. Niemelä O, Halkola AS, Bloigu A, et al. : Blood cell responses following heavy alcohol consumption coincide with changes in acute-phase reactants of inflammation, indices of hemolysis and immune responses to ethanol metabolites. Int. J. Mol. Sci. 2022; 23 (21): 12738. PubMed Abstract | Publisher Full Text | Free Full Text 3. Steffen BT, Duprez D, Bertoni AG, et al. : Lp(a)-related risk of heart failure is evident in whites but not in other racial/ethnic groups. Arterioscler. Thromb. Vasc. Biol. 2018; 38 (10): 2498–2504. PubMed Abstract | Publisher Full Text | Free Full Text 4. Ruixing Y, Shangling P, Hong C, et al. : Diet, alcohol consumption, and serum lipid levels of the middle-aged and elderly in the Guangxi Bai Ku Yao and Han populations. Alcohol. 2008; 42 (3): 219–229. PubMed Abstract | Publisher Full Text 5. Ayhan Y, Gürel ŞC, Karaca Ö, et al. : Association between ADH1C and ALDH2 polymorphisms and alcoholism in a Turkish sample. Nord. J. Psychiatry. 2015; 69 (3): 233–239. PubMed Abstract | Publisher Full Text 6. Hagström H: Alcohol consumption in concomitant liver disease: how much is too much? Curr. Hepatol. Rep. 2017; 16 (2): 152–157. Publisher Full Text 7. Nand N, Malhotra P, Dhoot DK: Clinical profile of alcoholic liver disease in a tertiary care centre and its correlation with type, amount and duration of alcohol consumption. J. Assoc. Physicians India. 2015; 63 (6): 14–20. PubMed Abstract 8. Malherbe DC, Messaoudi I: Transcriptional and epigenetic regulation of monocyte and macrophage dysfunction by chronic alcohol consumption. Front. Immunol. 2022; 13 : 911951. PubMed Abstract | Publisher Full Text | Free Full Text 9. Takeshita T, Kawai T, Morimoto K: Elevated levels of hemoglobin-associated acetaldehyde related to alcohol drinking in the atypical genotype of low Km aldehyde dehydrogenase. Cancer Res. 1997; 57 (7): 1241–1243. PubMed Abstract 10. Vetlugina TP, Savochkina DN, Roshchina OV, et al. : Red blood cell indices and T-lymphocytes in patients with alcoholism; protective potential of lithium ascorbate. Int J Appl Fundam Res. 2017; 2 (2): 272–276. Publisher Full Text 11. Zeng S, Rosati E, Saggau C, et al. : Candida albicans -specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe. 2023; 31 (3): 389–404.e7. PubMed Abstract | Publisher Full Text | Free Full Text 12. Shi X, DeLucia AL, Bao J, et al. : Alcohol abuse and disorder of granulopoiesis. Pharmacol. Ther. 2019; 198 : 206–219. PubMed Abstract | Publisher Full Text | Free Full Text 13. Silczuk A, Habrat B: Alcohol-induced thrombocytopenia: current review. Alcohol. 2020; 86 : 9–16. PubMed Abstract | Publisher Full Text 14. Smith C, Gasparetto M, Jordan C, et al. : The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Adv. Exp. Med. Biol. 2015; 815 : 349–359. PubMed Abstract | Publisher Full Text 15. Yokoyama A, Yokoyama T, Mizukami T, et al. : Platelet counts and genetic polymorphisms of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 in Japanese alcoholic men. Alcohol. Clin. Exp. Res. 2017; 41 (1): 171–178. PubMed Abstract | Publisher Full Text 16. Niemelä O, Parkkila S: Alcoholic macrocytosis – is there a role for acetaldehyde and adducts? Addict. Biol. 2004; 9 (1): 3–10. PubMed Abstract | Publisher Full Text 17. Topic A, Djukic M: Diagnostic characteristics and application of alcohol biomarkers. Clin. Lab. 2013; 59 (3-4): 233–245. PubMed Abstract 18. Andresen-Streichert H, Müller A, Glahn A, et al. : Alcohol biomarkers in clinical and forensic contexts. Dtsch. Arztebl. Int. 2018; 115 (18): 309–315. PubMed Abstract | Publisher Full Text | Free Full Text 19. Nagao T, Hirokawa M: Diagnosis and treatment of macrocytic anemias in adults. J Gen Fam Med. 2017; 18 (5): 200–204. PubMed Abstract | Publisher Full Text | Free Full Text 20. Sobral-Oliveira MB, Faintuch J, Guarita DR, et al. : Nutritional profile of asymptomatic alcoholic patients. Arq. Gastroenterol. 2011; 48 (2): 112–118. PubMed Abstract | Publisher Full Text 21. Palmiere C, Augsburger M: The postmortem diagnosis of alcoholic ketoacidosis. Alcohol Alcohol. 2014; 49 (3): 271–281. Publisher Full Text 22. King SE, Waddell JT, Corbin WR: A preliminary investigation of salivary α-amylase as a novel biomarker of subjective response to alcohol: a brief report. Exp. Clin. Psychopharmacol. 2023; 31 (5): 888–894. PubMed Abstract | Publisher Full Text | Free Full Text 23. Nater UM, La Marca R, Erni K, et al. : Alpha-amylase activity in blood increases after pharmacological, but not psychological, activation of the adrenergic system. PLoS One. 2015; 10 (6): e0130449. PubMed Abstract | Publisher Full Text | Free Full Text 24. Iluz-Freundlich D, Zhang M, Uhanova J, et al. : The relative expression of hepatocellular and cholestatic liver enzymes in adult patients with liver disease. Ann. Hepatol. 2020; 19 (2): 204–208. PubMed Abstract | Publisher Full Text 25. Kurmaeva D, Ye Y, Bakhytkyzy I, et al. : Associations between sheep meat intake frequency and blood plasma levels of metabolites and lipoproteins in healthy Uzbek adults. Metabolomics. 2023; 19 (5): 46. PubMed Abstract | Publisher Full Text | Free Full Text 26. Tan EZY, Lai LL, Vethakkan SR, et al. : Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus. J. Gastroenterol. Hepatol. 2021; 36 (3): 751–757. Publisher Full Text 27. Dolan V: Low serum creatinine as a marker for undisclosed alcohol abuse. J. Insur. Med. 2022; 49 (2): 114–116. PubMed Abstract | Publisher Full Text 28. Morell B, Dufour JF: Liver transplantation – when and for whom it should be performed. Ther. Umsch. 2011; 68 (12): 707–713. PubMed Abstract | Publisher Full Text 29. Gonzalez-Quintela A, Vidal C, Gude F: Alcohol, IgE and allergy. Addict. Biol. 2004; 9 (3-4): 195–204. Publisher Full Text 30. Garea MH, Alqasoumi AA, Alqahtani SA, et al. : Vitamin C as a potential ameliorating agent against hepatotoxicity among alcoholic abusers. Eur. Rev. Med. Pharmacol. Sci. 2023; 27 (8): 3322–3335. PubMed Abstract | Publisher Full Text 31. Long B, Lentz S, Gottlieb M: Alcoholic ketoacidosis: etiologies, evaluation, and management. J. Emerg. Med. 2021; 61 (6): 658–665. PubMed Abstract | Publisher Full Text 32. Gwiti P, Davidson F, Beresford P, et al. : Significant ketoacidosis at autopsy: a single-centre systematic review. J. Clin. Pathol. 2023; 76 (3): 185–188. PubMed Abstract | Publisher Full Text 33. Casey B, Hofstrand R, Patel D, et al. : Hypokalemia-induced cardiac arrest. Cureus. 2023; 15 (2): e35034. PubMed Abstract | Publisher Full Text | Free Full Text 34. Büyükkaragöz B, Bakkaloğlu SA: Serum osmolality and hyperosmolar states. Pediatr. Nephrol. 2023; 38 (4): 1013–1025. Publisher Full Text 35. Liu Y, Zhang Y, Wang H, et al. : AST and ALT as biomarkers of alcohol-induced liver damage. Hepatology. 2020; 73 (4): 890–900. Publisher Full Text 36. Vallet-Pichard A, Mallet V, Nalpas B, et al. : FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Hepatology. 2007; 46 (1): 32–36. Publisher Full Text 37. Kupari M, Koskinen P, Naveri H, et al. : Acute cardiovascular effects of alcohol. J. Hypertens. 1993; 11 (8): 823–830. Publisher Full Text 38. Zhang M, Wang X, Li J, et al. : Immune dysregulation in viral hepatitis and alcoholism. J. Clin. Invest. 2018; 128 (5): 2103–2115. Publisher Full Text 39. Nakamoto Y, Guidotti LG, Kuhlen CV, et al. : Immune pathogenesis of hepatocellular damage in hepatitis C virus infection. J. Hepatol. 2000; 32 (5): 818–826. Publisher Full Text 40. Tseomashko N, Syunyakov T, Khayredinova I, et al. : Population-Specific Biomarker Dataset for Alcohol Use Disorder in Uzbekistan. [dataset]. Zenodo. 2025. Publisher Full Text Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 24 Dec 2025 ADD YOUR COMMENT Comment Author details Author details 1 Republican Specialized Scientific and Practical Medical Center for Mental Health, Tashkent, Uzbekistan 2 International Centre for Education and Research in Neuropsychiatry (ICERN), Samara State Medical University,, Russia, Samara, Russian Federation 3 Mental-health Clinic No.1 named after N.A. Alexeev of the Moscow Healthcare Department, , Russia, Moscow, Russian Federation 4 Department of Psychiatry and Narcology of, Tashkent Medical Academy, Tashkent, Uzbekistan 5 Department of Narcology and Adolescent Psychopathology, of the Center for the Develop-ment of Professional Qualifications of Medical Workers, Tashkent, Uzbekistan 6 Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan Natalya Tseomashko Roles: Conceptualization, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing Timur Syunyakov Roles: Formal Analysis, Software, Supervision, Validation, Visualization, Writing – Review & Editing Inara Khayredinova Roles: Data Curation, Formal Analysis, Investigation, Writing – Original Draft Preparation Uktam Tadjibaev Roles: Data Curation, Investigation, Methodology Furkat Bahramov Roles: Data Curation, Investigation, Resources Zarifjon Ashurov Roles: Project Administration, Resources, Supervision Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (2) version 2 Revised Published: 19 May 2026, 14:1449 https://doi.org/10.12688/f1000research.172858.2 version 1 Published: 24 Dec 2025, 14:1449 https://doi.org/10.12688/f1000research.172858.1 Copyright © 2025 Tseomashko N et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Tseomashko N, Syunyakov T, Khayredinova I et al. Population-Specific Biomarker Signatures in Alcohol Use Disorder: Ethnic and Viral Influences in a Central Asian Cohort [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1449 ( https://doi.org/10.12688/f1000research.172858.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 24 Dec 2025 Views 0 Cite How to cite this report: Sinclair J and Morris J. Reviewer Report For: Population-Specific Biomarker Signatures in Alcohol Use Disorder: Ethnic and Viral Influences in a Central Asian Cohort [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1449 ( https://doi.org/ ) The direct URL for this report is: https://f1000research.com/articles/14-1449/v1#referee-response-464369 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 04 Mar 2026 Julia Sinclair , University of Southampton, Southampton, England, UK Julia Morris , University of Southampton, Southampton, England, UK Approved with Reservations VIEWS 0 https://doi.org/ General comments: This study is a helpful addition to the literature, in describing haematological and biochemical biomarkers, and comorbidities, in individuals with and without AUD and chronic viral illnesses in Uzbekistan. Terminology needs to be ... Continue reading READ ALL General comments: This study is a helpful addition to the literature, in describing haematological and biochemical biomarkers, and comorbidities, in individuals with and without AUD and chronic viral illnesses in Uzbekistan. Terminology needs to be clear and and more consistent when describing cases throughout the paper. For example, within the methodology, cases are described as those with a ‘F10.2 diagnosis of stage II chronic alcoholism’, and later in the paper, ‘stage 2 alcohol use disorder’ . The ICD-10 does not describe AUD as having ‘stages’, so the paper should clarify how cases have been defined (including where the data on diagnostic codes has been obtained from). Relatedly, patients with ‘mild AUD’ are excluded, and so the paper should describe how ‘mild AUD’ has been defined. Additionally, cases are described as ‘addicts’ within Figure 1, which is no longer considered an acceptable term in professional writing to describe individuals with substance use disorders. Abstract: The abstract could better orientate the reader to the purpose of the paper, by clarifying the viral infections studied refer to chronic viral infections (e.g. Hepatitis B, Hepatitis C, HIV) and not typically self-limiting viral infections (e.g. influenza). Methodology: Please include the specific dates of the 3-month study period, whether participants were inpatients or outpatients, and how biomarker values were selected if more than one value was available per participant? Relatedly, it is not clear if controls were selected from patients at the centre or from within another group – this information should be included. A brief sentence explaining the De Ritis ratio needs to be included in the methods section (rather than in the discussion). Please explain how data on participant BMI, ethnicity, comorbidities, and alcohol withdrawal symptoms was obtained, as well as how alcohol withdrawal was categorised as ‘mild’, ‘moderate’ or ‘severe’. Please also comment on whether all delusions/hallucinations referenced in the study are known to be related to alcohol withdrawal, or if these could be related to a primary mental illness, in addition to how this data on specific symptoms was obtained. The methods section states patients with ‘mild withdrawal symptoms’ were excluded. It would be helpful to explain why this decision was made, as it appears (from within the discussion) that patients with both no withdrawal symptoms, and those with severe withdrawal symptoms, were included. Results: Within the results section, a right shift in the differential count is said to be suggestive of megaloblastic anaemia or hepatic/renal impairment. I am not aware ‘right shift’ is a widely accepted term (as ‘left shift’ is) or that this is accepted as suggestive of megaloblastic anaemia or hepatic/renal impairment. Please provide further evidence supporting this statement. Discussion: The authors are encouraged to review their discussion to ensure that they do not make claims beyond the data presented or cited The term ‘granulocytopenia’ is used, however, data on eosinophils and basophils is not provided. Please clarify if this refers specifically to low neutrophils, or to low granulocytes (neutrophils, eosinophils and basophils). The reference to previous research on candida-albicans-specific Th17 cells would benefit from further explanation of its relevance to this work. The statement ‘these findings support including creatinine in the MELD score, a validated mortality predictor in end-stage liver disease’ is not adequately supported by the findings of the paper, as the paper does not explore mortality. Please adjust this statement as it is important not to talk beyond the data Please clarify the comment made regarding the small number of female participants, as females were explicitly excluded. Please clarify the following statement: ‘while low PLT has been associated with withdrawal-related neuropsychiatric complications, no such manifestations were observed in patients with severe thrombocytopenia here’. The paper cited here specifically comments on associations between thrombocytopenia and delirium tremens, and thrombocytopenia and alcohol-withdrawal seizures, when the current paper does not appear to have collected data on either delirium tremens or alcohol-withdrawal seizures. Relatedly, the current paper has analysed blood results categorically (low/normal/high), and therefore has limited ability to comment on the severity of any thrombocytopenia. The statement ‘the findings reinforce the utility of combining biochemical, haematological, and physiological markers to enhance diagnostic accuracy’ does not make sense without further context on what is being diagnosed (e.g. viral infections, AUD), reflection on why diagnostic accuracy may currently be difficult, and the clinical importance of accurate diagnosis. Supplementary tables: Within Table S1, please provide a legend with the abbreviations (e.g. LYM, MON etc.) written out in full. Please also provide the specific thresholds which have been defined as the normal range in the table. Within Table S2, please clarify if the glucose is a random level or fasted. Consistency in bilirubin labelling would be helpful (i.e. direct/indirect or conjugated/unconjugated), as this currently changes throughout the paper and table S2. Dataset: A participant ID is provided, and separately an ‘encrypted name, nation’. The encrypted name looks to very possibly include the patient’s actual initials. Please consider if this needs to be anonymised further, to meet data anonymity requirements. A ‘note’ column contains comorbidity information not required for replication of the study findings, and possibly identifying of individual participants if the recommended changes in the methodology (e.g. including specific dates) are made. Please consider removing this from the table. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Partly If applicable, is the statistical analysis and its interpretation appropriate? Partly Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Partly Competing Interests: No competing interests were disclosed. We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Sinclair J and Morris J. Reviewer Report For: Population-Specific Biomarker Signatures in Alcohol Use Disorder: Ethnic and Viral Influences in a Central Asian Cohort [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1449 ( https://doi.org/ ) The direct URL for this report is: https://f1000research.com/articles/14-1449/v1#referee-response-464369 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 19 May 2026 Natalya Tseomashko , Republican Specialized Scientific and Practical Medical Center for Mental Health, Tashkent, Uzbekistan 19 May 2026 Author Response Dear Reviewer, We would like to sincerely thank you for your careful and constructive review of our manuscript. We are grateful for your positive assessment that the study is a ... Continue reading Dear Reviewer, We would like to sincerely thank you for your careful and constructive review of our manuscript. We are grateful for your positive assessment that the study is a helpful addition to the literature on hematological and biochemical biomarkers and comorbidities in individuals with AUD and chronic viral illnesses in Uzbekistan. We also appreciate your detailed suggestions, which helped us improve the clarity, methodological transparency, terminology, interpretation, supplementary materials, and dataset anonymization. We have revised the manuscript carefully in response to all comments. In addition, the supplementary materials and dataset deposited in Zenodo were revised for clarity and further anonymization. No changes were made to the study groups, statistical analyses, numerical results, or reported conclusions. Below we provide a point-by-point response. General comment: Terminology needs to be clear and more consistent when describing cases throughout the paper. The reviewer noted inconsistent use of “stage II chronic alcoholism,” “stage 2 alcohol use disorder,” “mild AUD,” and the term “addicts” in Figure 1. Thank you for this important comment. We revised the terminology throughout the manuscript to improve consistency and to avoid stigmatizing language. The term “addicts” was removed and replaced with person-first terminology. We now consistently refer to the patient groups as “patients with AUD” or “AUD cohorts.” We also clarified that the diagnosis was alcohol use disorder according to ICD-10 code F10.2. The wording suggesting that ICD-10 defines AUD by “stages” was removed or revised. In the Methods section, we now specify that inclusion criteria were male sex, age 20-65 years, inpatient status, and a clinical diagnosis of AUD (ICD-10 F10.2), established by an addiction psychiatrist and supported by AUDIT. We also clarified the exclusion of individuals with mild alcohol-related conditions or clinically mild withdrawal presentations. The revised Methods state that individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. Abstract: The abstract could better orientate the reader by clarifying that the viral infections studied refer to chronic viral infections, such as hepatitis B, hepatitis C, and HIV. Thank you. We revised the Abstract to clarify this point. The Background now states that the study examined biomarker signatures in men with AUD in Uzbekistan, with and without chronic viral infections, specifically hepatitis B, hepatitis C, and HIV. This clarification was also applied throughout the manuscript, including the Methods, Results, Discussion, figure/table legends, and data descriptions. Methodology: Please include the specific dates of the 3-month study period, whether participants were inpatients or outpatients, and how biomarker values were selected if more than one value was available per participant. Thank you. We expanded the Methods section substantially. We now specify that clinical and laboratory data were collected from 19 March to 22 June 2025. We also clarify that patients were recruited from inpatient units of the Republican Specialized Scientific and Practical Medical Center for Mental Health. We added that laboratory measurements were obtained at admission, before treatment initiation, and were considered baseline values. Only admission values were included in the analysis, and follow-up measurements during treatment were excluded. This was added to clarify how biomarker values were selected. Methodology: It is not clear whether controls were selected from patients at the centre or from another group. Thank you for noting this. We clarified the control group source. The revised Methods state that the control group consisted of male volunteers of approximately similar age, including employees of the same institution and relatives of employees. Controls had no history of alcohol use disorder or psychoactive substance use, as confirmed by questionnaire-based screening and clinical assessment. We also clarified that one initially screened control participant was excluded because of a self-reported history of chronic hepatitis B, as the control group was defined to include individuals without known chronic viral infections. Methodology: A brief sentence explaining the De Ritis ratio needs to be included in the Methods section rather than in the Discussion. Thank you. We added a methodological explanation in the Data Collection section. The revised manuscript now states that the De Ritis ratio was calculated as the ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT) and was used to characterize patterns of liver injury. Methodology: Please explain how data on BMI, ethnicity, comorbidities, and alcohol withdrawal symptoms were obtained, and how withdrawal was categorized as mild, moderate, or severe. Thank you. We expanded the Data Collection and Inclusion/Exclusion Criteria sections. The revised Methods now state that data on age, ethnicity, comorbidities, alcohol-use history, alcohol withdrawal symptoms, and clinical status were obtained from medical records, physician assessments, patient interviews, available collateral history, ultrasound reports, and documented diagnoses. Anthropometric data, including height and weight, were collected from medical records and questionnaires, and BMI was calculated as weight in kilograms divided by height in meters squared. We also added a detailed explanation of alcohol withdrawal severity classification. Withdrawal severity was assessed clinically by the treating addiction psychiatrist and classified as mild, moderate, or severe according to the intensity of autonomic, somatic, and neuropsychiatric symptoms, including tremor, agitation, anxiety, sleep disturbance, nausea/vomiting, disorientation, hallucinations, delusional symptoms, and the need for inpatient monitoring or pharmacological management. Mild withdrawal was defined as limited autonomic or anxiety-related symptoms without clinically significant neuropsychiatric manifestations or somatic instability. Moderate withdrawal included more pronounced symptoms requiring inpatient observation and treatment, whereas severe withdrawal was characterized by delirium, hallucinations, delusional symptoms, marked agitation, or clinically significant somatic instability. Methodology: Please comment on whether delusions/hallucinations were related to alcohol withdrawal or could be related to primary mental illness, and how these data were obtained. Thank you. We added a clarification in the Data Collection section. The revised manuscript states that delirium, hallucinations, and delusional symptoms were recorded only when documented by the treating addiction psychiatrist during the withdrawal episode. These data were obtained from clinical examination, patient interview, medical history, available collateral history, and medical record review. We also clarified that symptoms were considered withdrawal-related when they occurred in the context of alcohol withdrawal and were not documented as part of a primary psychiatric disorder. According to the medical records, these patients had no previous registration or documented history of primary psychotic disorders. Methodology: The Methods section states that patients with mild withdrawal symptoms were excluded. Please explain why this decision was made. Thank you. We clarified this point in the Study Design and Population section and in the Inclusion/Exclusion Criteria section. Individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. This was intended to maintain clinical comparability within the analytical cohort. Results: The statement regarding “right shift” in the differential count and its interpretation as suggestive of megaloblastic anemia or hepatic/renal impairment requires further support. Thank you for this very helpful comment. We revised this section to avoid unsupported interpretation. The term “right shift” was removed. We now state that an increased proportion of segmented neutrophils was observed in 7.6–9.8% of patients; however, because direct morphological assessment of neutrophil hypersegmentation was not performed, this finding should be interpreted cautiously and cannot be used to infer megaloblastic anemia or hepatic/renal impairment. This revision ensures that the interpretation remains aligned with the data actually available in the study. Discussion: Please review the Discussion to ensure that claims do not go beyond the data presented or cited. Thank you. We carefully revised the Discussion to make the interpretation more cautious and better aligned with the available data. Several statements were softened or clarified. For example, causal or overly strong wording was revised to more cautious language such as “may reflect,” “may aggravate,” “suggesting a greater likelihood,” and “should be interpreted cautiously.” We also revised the interpretation of neuropsychiatric symptoms, platelet counts, creatinine/MELD, ROC findings, bilirubin findings, and biomarker diagnostic utility to avoid overinterpretation. Discussion: The term “granulocytopenia” is used, but data on eosinophils and basophils are not provided. Please clarify whether this refers specifically to low neutrophils or to low granulocytes. Thank you. We revised this terminology. Because eosinophil and basophil data were not included, we removed the broader term “granulocytopenia” where it could be misleading and clarified the finding as neutropenia/neutrophilic granulocyte compartment suppression. The revised Discussion now states that alcohol-related disruption of granulopoiesis has been described as a mechanism contributing to impaired innate immune defense and increased susceptibility to infection. However, in the present AUD cohorts, neutropenia was rare and comparable between virus-positive and virus-negative patients, suggesting that suppression of the neutrophilic granulocyte compartment was not a prominent hematological feature in these patients. Discussion: The reference to previous research on Candida albicans-specific Th17 cells would benefit from further explanation of its relevance to this work. Thank you. We expanded this part of the Discussion to better explain the relevance of the cited work. The revised text now explains that inflammatory marker abnormalities may reflect not only viral-associated inflammatory burden but also alcohol-related disruption of gut-liver immune signaling. We added that Zeng et al. showed that chronic alcohol exposure is associated with intestinal fungal dysbiosis and increased Candida albicans-specific Th17 responses, with these cells detected in the circulation and liver of patients with alcohol-associated liver disease. We also noted that experimental models showed ethanol-associated migration of Candida albicans-specific Th17 cells from the intestine to the liver, where IL-17-mediated signaling contributed to hepatic inflammation and injury. This explanation was added to clarify why gut-derived microbial/fungal immune pathways may be relevant to systemic and hepatic inflammation in patients with AUD and chronic viral comorbidity. Discussion: The statement that the findings support including creatinine in the MELD score is not adequately supported, as mortality was not explored. Thank you. We agree and revised this section substantially. The unsupported statement was removed. The revised Discussion now states that creatinine was significantly lower in patients with AUD, consistent with prior reports. We explain that, in the context of chronic alcohol exposure, reduced creatinine may reflect lower skeletal muscle mass, malnutrition, or altered protein metabolism rather than preserved renal function. We also clarified that creatinine remains an important component of liver disease severity assessment, including the MELD score, where it is considered together with bilirubin and INR to support risk stratification in advanced liver disease. We no longer imply that our findings validate mortality prediction. Instead, we state that lower creatinine in the present cohorts should be interpreted as part of the broader metabolic and somatic profile of patients with AUD rather than as an isolated renal marker. Discussion: Please clarify the comment regarding the small number of female participants, as females were explicitly excluded. Thank you. We revised the Limitations section to clarify this point. The revised text states that the analysis was restricted to male patients because only eight female patients met the initial screening criteria, which was insufficient for meaningful sex-stratified analysis. Given known sex-related differences in alcohol metabolism, body composition, and biochemical and hematological profiles, women were therefore excluded from the final analytical dataset. We also added that the findings should be interpreted as primarily applicable to male patients with AUD, and that future studies should include adequately powered female cohorts. Discussion: Please clarify the statement regarding low PLT and withdrawal-related neuropsychiatric complications, as the cited paper refers to delirium tremens and withdrawal seizures, and the current paper did not appear to collect these outcomes. The current paper also analyzed blood results categorically and has limited ability to comment on severity of thrombocytopenia. Thank you for this important clarification. We revised this section to avoid overinterpretation. We no longer refer to severe thrombocytopenia as an outcome category. Instead, we provide the platelet findings in relation to the reference range and explicitly state the available clinical data. The revised Discussion now states that thrombocytopenia was observed in patients with AUD. We added median PLT values across cohorts and the proportions of participants with PLT values below the reference range. We also clarified that, although platelet counts below 119,000/μL have been associated with increased risk of withdrawal seizures and delirium tremens in previous research, clinically documented delirium and hallucinations during withdrawal were recorded in only 16 of 292 patients with AUD in our cohort; among them, only one had PLT below the reference range, one had PLT at the lower reference limit, and 14 had values within the reference range. We therefore revised the conclusion to state that reduced PLT was an important hematological feature of AUD but showed no clear correspondence with recorded withdrawal-related delirium or hallucinations in this cohort. Discussion: The statement about combining biochemical, hematological, and physiological markers to enhance diagnostic accuracy needs further context on what is being diagnosed, why diagnostic accuracy may be difficult, and the clinical importance of accurate diagnosis. Thank you. We revised the ROC interpretation in both the Results and Discussion sections. We clarified that two diagnostic comparisons were assessed: first, discrimination between all patients with AUD and alcohol-free controls; second, differentiation between patients with AUD and chronic viral infection and patients with AUD without chronic viral infection. We also clarified that AUROC was used to quantify discriminatory performance and that AUROC values below 0.5 reflected inverse discrimination according to the predefined class coding, rather than necessarily indicating absence of discriminatory value. In the Discussion, we revised the statement to clarify that combined biomarker panels may be more informative than isolated markers for distinguishing AUD from alcohol-free controls and for identifying viral comorbidity within AUD cohorts. We also added clinical context: chronic alcohol exposure and viral infections can produce overlapping hepatic, inflammatory, and metabolic abnormalities, making interpretation of single laboratory parameters difficult. We further clarified that markers with limited discriminatory performance, including platelets, hemoglobin, and BMI, should be interpreted as supportive clinical features rather than standalone diagnostic indicators. Supplementary tables: Within Table S1, please provide a legend with abbreviations written out in full and provide the thresholds defined as normal range. Thank you. Supplementary Table S1 was revised. We added a legend defining hematological abbreviations, including Hb, LYM, MCV, MON, MPV, NEUT, PLT, ESR, and WBC. We also added the specific reference intervals used to define low, normal, and high values. Supplementary tables: Within Table S2, please clarify whether glucose is random or fasted. Thank you. Supplementary Table S2 was revised to clarify glucose sampling. We added that glucose values in the patient group represent random/non-fasting blood glucose measured at admission, whereas blood samples from controls were obtained under fasting conditions. This clarification was also added to the Methods section. Supplementary tables: Consistency in bilirubin labeling would be helpful. Thank you. We harmonized bilirubin terminology throughout the manuscript and supplementary materials. We now use direct (conjugated) bilirubin and indirect (unconjugated) bilirubin consistently where relevant. Dataset: Participant ID and “encrypted name, nation” may contain identifying information. Please consider whether further anonymization is needed. Thank you. We carefully reviewed and revised the dataset. The dataset file deposited in Zenodo was additionally anonymized. Potentially identifying or non-essential fields, including the encrypted name and nationality-related field, were removed. The dataset now retains anonymized participant IDs and the variables required for reproducibility of the analysis. Dataset: The “note” column contains comorbidity information not required for replication and may be identifying if specific dates are included. Please consider removing this column. Thank you. We removed the free-text note column from the dataset to reduce re-identification risk. Comorbidity-related information necessary for the analysis is retained in structured, analyzable variables, while potentially identifying free-text information was removed. Additional data and references During the revision, we also checked the reference list and corrected/replaced several references where needed to ensure that all cited sources accurately support the corresponding statements. The Zenodo repository was updated to include the additionally de-identified underlying dataset and clarified extended data files. No changes were made to study groups, statistical analyses, numerical results, or reported conclusions. We are grateful to the reviewer for the detailed and constructive comments. We believe that the revised version is clearer, more transparent, more cautious in interpretation, and better aligned with the available data and reporting standards. Dear Reviewer, We would like to sincerely thank you for your careful and constructive review of our manuscript. We are grateful for your positive assessment that the study is a helpful addition to the literature on hematological and biochemical biomarkers and comorbidities in individuals with AUD and chronic viral illnesses in Uzbekistan. We also appreciate your detailed suggestions, which helped us improve the clarity, methodological transparency, terminology, interpretation, supplementary materials, and dataset anonymization. We have revised the manuscript carefully in response to all comments. In addition, the supplementary materials and dataset deposited in Zenodo were revised for clarity and further anonymization. No changes were made to the study groups, statistical analyses, numerical results, or reported conclusions. Below we provide a point-by-point response. General comment: Terminology needs to be clear and more consistent when describing cases throughout the paper. The reviewer noted inconsistent use of “stage II chronic alcoholism,” “stage 2 alcohol use disorder,” “mild AUD,” and the term “addicts” in Figure 1. Thank you for this important comment. We revised the terminology throughout the manuscript to improve consistency and to avoid stigmatizing language. The term “addicts” was removed and replaced with person-first terminology. We now consistently refer to the patient groups as “patients with AUD” or “AUD cohorts.” We also clarified that the diagnosis was alcohol use disorder according to ICD-10 code F10.2. The wording suggesting that ICD-10 defines AUD by “stages” was removed or revised. In the Methods section, we now specify that inclusion criteria were male sex, age 20-65 years, inpatient status, and a clinical diagnosis of AUD (ICD-10 F10.2), established by an addiction psychiatrist and supported by AUDIT. We also clarified the exclusion of individuals with mild alcohol-related conditions or clinically mild withdrawal presentations. The revised Methods state that individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. Abstract: The abstract could better orientate the reader by clarifying that the viral infections studied refer to chronic viral infections, such as hepatitis B, hepatitis C, and HIV. Thank you. We revised the Abstract to clarify this point. The Background now states that the study examined biomarker signatures in men with AUD in Uzbekistan, with and without chronic viral infections, specifically hepatitis B, hepatitis C, and HIV. This clarification was also applied throughout the manuscript, including the Methods, Results, Discussion, figure/table legends, and data descriptions. Methodology: Please include the specific dates of the 3-month study period, whether participants were inpatients or outpatients, and how biomarker values were selected if more than one value was available per participant. Thank you. We expanded the Methods section substantially. We now specify that clinical and laboratory data were collected from 19 March to 22 June 2025. We also clarify that patients were recruited from inpatient units of the Republican Specialized Scientific and Practical Medical Center for Mental Health. We added that laboratory measurements were obtained at admission, before treatment initiation, and were considered baseline values. Only admission values were included in the analysis, and follow-up measurements during treatment were excluded. This was added to clarify how biomarker values were selected. Methodology: It is not clear whether controls were selected from patients at the centre or from another group. Thank you for noting this. We clarified the control group source. The revised Methods state that the control group consisted of male volunteers of approximately similar age, including employees of the same institution and relatives of employees. Controls had no history of alcohol use disorder or psychoactive substance use, as confirmed by questionnaire-based screening and clinical assessment. We also clarified that one initially screened control participant was excluded because of a self-reported history of chronic hepatitis B, as the control group was defined to include individuals without known chronic viral infections. Methodology: A brief sentence explaining the De Ritis ratio needs to be included in the Methods section rather than in the Discussion. Thank you. We added a methodological explanation in the Data Collection section. The revised manuscript now states that the De Ritis ratio was calculated as the ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT) and was used to characterize patterns of liver injury. Methodology: Please explain how data on BMI, ethnicity, comorbidities, and alcohol withdrawal symptoms were obtained, and how withdrawal was categorized as mild, moderate, or severe. Thank you. We expanded the Data Collection and Inclusion/Exclusion Criteria sections. The revised Methods now state that data on age, ethnicity, comorbidities, alcohol-use history, alcohol withdrawal symptoms, and clinical status were obtained from medical records, physician assessments, patient interviews, available collateral history, ultrasound reports, and documented diagnoses. Anthropometric data, including height and weight, were collected from medical records and questionnaires, and BMI was calculated as weight in kilograms divided by height in meters squared. We also added a detailed explanation of alcohol withdrawal severity classification. Withdrawal severity was assessed clinically by the treating addiction psychiatrist and classified as mild, moderate, or severe according to the intensity of autonomic, somatic, and neuropsychiatric symptoms, including tremor, agitation, anxiety, sleep disturbance, nausea/vomiting, disorientation, hallucinations, delusional symptoms, and the need for inpatient monitoring or pharmacological management. Mild withdrawal was defined as limited autonomic or anxiety-related symptoms without clinically significant neuropsychiatric manifestations or somatic instability. Moderate withdrawal included more pronounced symptoms requiring inpatient observation and treatment, whereas severe withdrawal was characterized by delirium, hallucinations, delusional symptoms, marked agitation, or clinically significant somatic instability. Methodology: Please comment on whether delusions/hallucinations were related to alcohol withdrawal or could be related to primary mental illness, and how these data were obtained. Thank you. We added a clarification in the Data Collection section. The revised manuscript states that delirium, hallucinations, and delusional symptoms were recorded only when documented by the treating addiction psychiatrist during the withdrawal episode. These data were obtained from clinical examination, patient interview, medical history, available collateral history, and medical record review. We also clarified that symptoms were considered withdrawal-related when they occurred in the context of alcohol withdrawal and were not documented as part of a primary psychiatric disorder. According to the medical records, these patients had no previous registration or documented history of primary psychotic disorders. Methodology: The Methods section states that patients with mild withdrawal symptoms were excluded. Please explain why this decision was made. Thank you. We clarified this point in the Study Design and Population section and in the Inclusion/Exclusion Criteria section. Individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. This was intended to maintain clinical comparability within the analytical cohort. Results: The statement regarding “right shift” in the differential count and its interpretation as suggestive of megaloblastic anemia or hepatic/renal impairment requires further support. Thank you for this very helpful comment. We revised this section to avoid unsupported interpretation. The term “right shift” was removed. We now state that an increased proportion of segmented neutrophils was observed in 7.6–9.8% of patients; however, because direct morphological assessment of neutrophil hypersegmentation was not performed, this finding should be interpreted cautiously and cannot be used to infer megaloblastic anemia or hepatic/renal impairment. This revision ensures that the interpretation remains aligned with the data actually available in the study. Discussion: Please review the Discussion to ensure that claims do not go beyond the data presented or cited. Thank you. We carefully revised the Discussion to make the interpretation more cautious and better aligned with the available data. Several statements were softened or clarified. For example, causal or overly strong wording was revised to more cautious language such as “may reflect,” “may aggravate,” “suggesting a greater likelihood,” and “should be interpreted cautiously.” We also revised the interpretation of neuropsychiatric symptoms, platelet counts, creatinine/MELD, ROC findings, bilirubin findings, and biomarker diagnostic utility to avoid overinterpretation. Discussion: The term “granulocytopenia” is used, but data on eosinophils and basophils are not provided. Please clarify whether this refers specifically to low neutrophils or to low granulocytes. Thank you. We revised this terminology. Because eosinophil and basophil data were not included, we removed the broader term “granulocytopenia” where it could be misleading and clarified the finding as neutropenia/neutrophilic granulocyte compartment suppression. The revised Discussion now states that alcohol-related disruption of granulopoiesis has been described as a mechanism contributing to impaired innate immune defense and increased susceptibility to infection. However, in the present AUD cohorts, neutropenia was rare and comparable between virus-positive and virus-negative patients, suggesting that suppression of the neutrophilic granulocyte compartment was not a prominent hematological feature in these patients. Discussion: The reference to previous research on Candida albicans-specific Th17 cells would benefit from further explanation of its relevance to this work. Thank you. We expanded this part of the Discussion to better explain the relevance of the cited work. The revised text now explains that inflammatory marker abnormalities may reflect not only viral-associated inflammatory burden but also alcohol-related disruption of gut-liver immune signaling. We added that Zeng et al. showed that chronic alcohol exposure is associated with intestinal fungal dysbiosis and increased Candida albicans-specific Th17 responses, with these cells detected in the circulation and liver of patients with alcohol-associated liver disease. We also noted that experimental models showed ethanol-associated migration of Candida albicans-specific Th17 cells from the intestine to the liver, where IL-17-mediated signaling contributed to hepatic inflammation and injury. This explanation was added to clarify why gut-derived microbial/fungal immune pathways may be relevant to systemic and hepatic inflammation in patients with AUD and chronic viral comorbidity. Discussion: The statement that the findings support including creatinine in the MELD score is not adequately supported, as mortality was not explored. Thank you. We agree and revised this section substantially. The unsupported statement was removed. The revised Discussion now states that creatinine was significantly lower in patients with AUD, consistent with prior reports. We explain that, in the context of chronic alcohol exposure, reduced creatinine may reflect lower skeletal muscle mass, malnutrition, or altered protein metabolism rather than preserved renal function. We also clarified that creatinine remains an important component of liver disease severity assessment, including the MELD score, where it is considered together with bilirubin and INR to support risk stratification in advanced liver disease. We no longer imply that our findings validate mortality prediction. Instead, we state that lower creatinine in the present cohorts should be interpreted as part of the broader metabolic and somatic profile of patients with AUD rather than as an isolated renal marker. Discussion: Please clarify the comment regarding the small number of female participants, as females were explicitly excluded. Thank you. We revised the Limitations section to clarify this point. The revised text states that the analysis was restricted to male patients because only eight female patients met the initial screening criteria, which was insufficient for meaningful sex-stratified analysis. Given known sex-related differences in alcohol metabolism, body composition, and biochemical and hematological profiles, women were therefore excluded from the final analytical dataset. We also added that the findings should be interpreted as primarily applicable to male patients with AUD, and that future studies should include adequately powered female cohorts. Discussion: Please clarify the statement regarding low PLT and withdrawal-related neuropsychiatric complications, as the cited paper refers to delirium tremens and withdrawal seizures, and the current paper did not appear to collect these outcomes. The current paper also analyzed blood results categorically and has limited ability to comment on severity of thrombocytopenia. Thank you for this important clarification. We revised this section to avoid overinterpretation. We no longer refer to severe thrombocytopenia as an outcome category. Instead, we provide the platelet findings in relation to the reference range and explicitly state the available clinical data. The revised Discussion now states that thrombocytopenia was observed in patients with AUD. We added median PLT values across cohorts and the proportions of participants with PLT values below the reference range. We also clarified that, although platelet counts below 119,000/μL have been associated with increased risk of withdrawal seizures and delirium tremens in previous research, clinically documented delirium and hallucinations during withdrawal were recorded in only 16 of 292 patients with AUD in our cohort; among them, only one had PLT below the reference range, one had PLT at the lower reference limit, and 14 had values within the reference range. We therefore revised the conclusion to state that reduced PLT was an important hematological feature of AUD but showed no clear correspondence with recorded withdrawal-related delirium or hallucinations in this cohort. Discussion: The statement about combining biochemical, hematological, and physiological markers to enhance diagnostic accuracy needs further context on what is being diagnosed, why diagnostic accuracy may be difficult, and the clinical importance of accurate diagnosis. Thank you. We revised the ROC interpretation in both the Results and Discussion sections. We clarified that two diagnostic comparisons were assessed: first, discrimination between all patients with AUD and alcohol-free controls; second, differentiation between patients with AUD and chronic viral infection and patients with AUD without chronic viral infection. We also clarified that AUROC was used to quantify discriminatory performance and that AUROC values below 0.5 reflected inverse discrimination according to the predefined class coding, rather than necessarily indicating absence of discriminatory value. In the Discussion, we revised the statement to clarify that combined biomarker panels may be more informative than isolated markers for distinguishing AUD from alcohol-free controls and for identifying viral comorbidity within AUD cohorts. We also added clinical context: chronic alcohol exposure and viral infections can produce overlapping hepatic, inflammatory, and metabolic abnormalities, making interpretation of single laboratory parameters difficult. We further clarified that markers with limited discriminatory performance, including platelets, hemoglobin, and BMI, should be interpreted as supportive clinical features rather than standalone diagnostic indicators. Supplementary tables: Within Table S1, please provide a legend with abbreviations written out in full and provide the thresholds defined as normal range. Thank you. Supplementary Table S1 was revised. We added a legend defining hematological abbreviations, including Hb, LYM, MCV, MON, MPV, NEUT, PLT, ESR, and WBC. We also added the specific reference intervals used to define low, normal, and high values. Supplementary tables: Within Table S2, please clarify whether glucose is random or fasted. Thank you. Supplementary Table S2 was revised to clarify glucose sampling. We added that glucose values in the patient group represent random/non-fasting blood glucose measured at admission, whereas blood samples from controls were obtained under fasting conditions. This clarification was also added to the Methods section. Supplementary tables: Consistency in bilirubin labeling would be helpful. Thank you. We harmonized bilirubin terminology throughout the manuscript and supplementary materials. We now use direct (conjugated) bilirubin and indirect (unconjugated) bilirubin consistently where relevant. Dataset: Participant ID and “encrypted name, nation” may contain identifying information. Please consider whether further anonymization is needed. Thank you. We carefully reviewed and revised the dataset. The dataset file deposited in Zenodo was additionally anonymized. Potentially identifying or non-essential fields, including the encrypted name and nationality-related field, were removed. The dataset now retains anonymized participant IDs and the variables required for reproducibility of the analysis. Dataset: The “note” column contains comorbidity information not required for replication and may be identifying if specific dates are included. Please consider removing this column. Thank you. We removed the free-text note column from the dataset to reduce re-identification risk. Comorbidity-related information necessary for the analysis is retained in structured, analyzable variables, while potentially identifying free-text information was removed. Additional data and references During the revision, we also checked the reference list and corrected/replaced several references where needed to ensure that all cited sources accurately support the corresponding statements. The Zenodo repository was updated to include the additionally de-identified underlying dataset and clarified extended data files. No changes were made to study groups, statistical analyses, numerical results, or reported conclusions. We are grateful to the reviewer for the detailed and constructive comments. We believe that the revised version is clearer, more transparent, more cautious in interpretation, and better aligned with the available data and reporting standards. Competing Interests: The authors declare that they have no competing interests. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 19 May 2026 Natalya Tseomashko , Republican Specialized Scientific and Practical Medical Center for Mental Health, Tashkent, Uzbekistan 19 May 2026 Author Response Dear Reviewer, We would like to sincerely thank you for your careful and constructive review of our manuscript. We are grateful for your positive assessment that the study is a ... Continue reading Dear Reviewer, We would like to sincerely thank you for your careful and constructive review of our manuscript. We are grateful for your positive assessment that the study is a helpful addition to the literature on hematological and biochemical biomarkers and comorbidities in individuals with AUD and chronic viral illnesses in Uzbekistan. We also appreciate your detailed suggestions, which helped us improve the clarity, methodological transparency, terminology, interpretation, supplementary materials, and dataset anonymization. We have revised the manuscript carefully in response to all comments. In addition, the supplementary materials and dataset deposited in Zenodo were revised for clarity and further anonymization. No changes were made to the study groups, statistical analyses, numerical results, or reported conclusions. Below we provide a point-by-point response. General comment: Terminology needs to be clear and more consistent when describing cases throughout the paper. The reviewer noted inconsistent use of “stage II chronic alcoholism,” “stage 2 alcohol use disorder,” “mild AUD,” and the term “addicts” in Figure 1. Thank you for this important comment. We revised the terminology throughout the manuscript to improve consistency and to avoid stigmatizing language. The term “addicts” was removed and replaced with person-first terminology. We now consistently refer to the patient groups as “patients with AUD” or “AUD cohorts.” We also clarified that the diagnosis was alcohol use disorder according to ICD-10 code F10.2. The wording suggesting that ICD-10 defines AUD by “stages” was removed or revised. In the Methods section, we now specify that inclusion criteria were male sex, age 20-65 years, inpatient status, and a clinical diagnosis of AUD (ICD-10 F10.2), established by an addiction psychiatrist and supported by AUDIT. We also clarified the exclusion of individuals with mild alcohol-related conditions or clinically mild withdrawal presentations. The revised Methods state that individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. Abstract: The abstract could better orientate the reader by clarifying that the viral infections studied refer to chronic viral infections, such as hepatitis B, hepatitis C, and HIV. Thank you. We revised the Abstract to clarify this point. The Background now states that the study examined biomarker signatures in men with AUD in Uzbekistan, with and without chronic viral infections, specifically hepatitis B, hepatitis C, and HIV. This clarification was also applied throughout the manuscript, including the Methods, Results, Discussion, figure/table legends, and data descriptions. Methodology: Please include the specific dates of the 3-month study period, whether participants were inpatients or outpatients, and how biomarker values were selected if more than one value was available per participant. Thank you. We expanded the Methods section substantially. We now specify that clinical and laboratory data were collected from 19 March to 22 June 2025. We also clarify that patients were recruited from inpatient units of the Republican Specialized Scientific and Practical Medical Center for Mental Health. We added that laboratory measurements were obtained at admission, before treatment initiation, and were considered baseline values. Only admission values were included in the analysis, and follow-up measurements during treatment were excluded. This was added to clarify how biomarker values were selected. Methodology: It is not clear whether controls were selected from patients at the centre or from another group. Thank you for noting this. We clarified the control group source. The revised Methods state that the control group consisted of male volunteers of approximately similar age, including employees of the same institution and relatives of employees. Controls had no history of alcohol use disorder or psychoactive substance use, as confirmed by questionnaire-based screening and clinical assessment. We also clarified that one initially screened control participant was excluded because of a self-reported history of chronic hepatitis B, as the control group was defined to include individuals without known chronic viral infections. Methodology: A brief sentence explaining the De Ritis ratio needs to be included in the Methods section rather than in the Discussion. Thank you. We added a methodological explanation in the Data Collection section. The revised manuscript now states that the De Ritis ratio was calculated as the ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT) and was used to characterize patterns of liver injury. Methodology: Please explain how data on BMI, ethnicity, comorbidities, and alcohol withdrawal symptoms were obtained, and how withdrawal was categorized as mild, moderate, or severe. Thank you. We expanded the Data Collection and Inclusion/Exclusion Criteria sections. The revised Methods now state that data on age, ethnicity, comorbidities, alcohol-use history, alcohol withdrawal symptoms, and clinical status were obtained from medical records, physician assessments, patient interviews, available collateral history, ultrasound reports, and documented diagnoses. Anthropometric data, including height and weight, were collected from medical records and questionnaires, and BMI was calculated as weight in kilograms divided by height in meters squared. We also added a detailed explanation of alcohol withdrawal severity classification. Withdrawal severity was assessed clinically by the treating addiction psychiatrist and classified as mild, moderate, or severe according to the intensity of autonomic, somatic, and neuropsychiatric symptoms, including tremor, agitation, anxiety, sleep disturbance, nausea/vomiting, disorientation, hallucinations, delusional symptoms, and the need for inpatient monitoring or pharmacological management. Mild withdrawal was defined as limited autonomic or anxiety-related symptoms without clinically significant neuropsychiatric manifestations or somatic instability. Moderate withdrawal included more pronounced symptoms requiring inpatient observation and treatment, whereas severe withdrawal was characterized by delirium, hallucinations, delusional symptoms, marked agitation, or clinically significant somatic instability. Methodology: Please comment on whether delusions/hallucinations were related to alcohol withdrawal or could be related to primary mental illness, and how these data were obtained. Thank you. We added a clarification in the Data Collection section. The revised manuscript states that delirium, hallucinations, and delusional symptoms were recorded only when documented by the treating addiction psychiatrist during the withdrawal episode. These data were obtained from clinical examination, patient interview, medical history, available collateral history, and medical record review. We also clarified that symptoms were considered withdrawal-related when they occurred in the context of alcohol withdrawal and were not documented as part of a primary psychiatric disorder. According to the medical records, these patients had no previous registration or documented history of primary psychotic disorders. Methodology: The Methods section states that patients with mild withdrawal symptoms were excluded. Please explain why this decision was made. Thank you. We clarified this point in the Study Design and Population section and in the Inclusion/Exclusion Criteria section. Individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. This was intended to maintain clinical comparability within the analytical cohort. Results: The statement regarding “right shift” in the differential count and its interpretation as suggestive of megaloblastic anemia or hepatic/renal impairment requires further support. Thank you for this very helpful comment. We revised this section to avoid unsupported interpretation. The term “right shift” was removed. We now state that an increased proportion of segmented neutrophils was observed in 7.6–9.8% of patients; however, because direct morphological assessment of neutrophil hypersegmentation was not performed, this finding should be interpreted cautiously and cannot be used to infer megaloblastic anemia or hepatic/renal impairment. This revision ensures that the interpretation remains aligned with the data actually available in the study. Discussion: Please review the Discussion to ensure that claims do not go beyond the data presented or cited. Thank you. We carefully revised the Discussion to make the interpretation more cautious and better aligned with the available data. Several statements were softened or clarified. For example, causal or overly strong wording was revised to more cautious language such as “may reflect,” “may aggravate,” “suggesting a greater likelihood,” and “should be interpreted cautiously.” We also revised the interpretation of neuropsychiatric symptoms, platelet counts, creatinine/MELD, ROC findings, bilirubin findings, and biomarker diagnostic utility to avoid overinterpretation. Discussion: The term “granulocytopenia” is used, but data on eosinophils and basophils are not provided. Please clarify whether this refers specifically to low neutrophils or to low granulocytes. Thank you. We revised this terminology. Because eosinophil and basophil data were not included, we removed the broader term “granulocytopenia” where it could be misleading and clarified the finding as neutropenia/neutrophilic granulocyte compartment suppression. The revised Discussion now states that alcohol-related disruption of granulopoiesis has been described as a mechanism contributing to impaired innate immune defense and increased susceptibility to infection. However, in the present AUD cohorts, neutropenia was rare and comparable between virus-positive and virus-negative patients, suggesting that suppression of the neutrophilic granulocyte compartment was not a prominent hematological feature in these patients. Discussion: The reference to previous research on Candida albicans-specific Th17 cells would benefit from further explanation of its relevance to this work. Thank you. We expanded this part of the Discussion to better explain the relevance of the cited work. The revised text now explains that inflammatory marker abnormalities may reflect not only viral-associated inflammatory burden but also alcohol-related disruption of gut-liver immune signaling. We added that Zeng et al. showed that chronic alcohol exposure is associated with intestinal fungal dysbiosis and increased Candida albicans-specific Th17 responses, with these cells detected in the circulation and liver of patients with alcohol-associated liver disease. We also noted that experimental models showed ethanol-associated migration of Candida albicans-specific Th17 cells from the intestine to the liver, where IL-17-mediated signaling contributed to hepatic inflammation and injury. This explanation was added to clarify why gut-derived microbial/fungal immune pathways may be relevant to systemic and hepatic inflammation in patients with AUD and chronic viral comorbidity. Discussion: The statement that the findings support including creatinine in the MELD score is not adequately supported, as mortality was not explored. Thank you. We agree and revised this section substantially. The unsupported statement was removed. The revised Discussion now states that creatinine was significantly lower in patients with AUD, consistent with prior reports. We explain that, in the context of chronic alcohol exposure, reduced creatinine may reflect lower skeletal muscle mass, malnutrition, or altered protein metabolism rather than preserved renal function. We also clarified that creatinine remains an important component of liver disease severity assessment, including the MELD score, where it is considered together with bilirubin and INR to support risk stratification in advanced liver disease. We no longer imply that our findings validate mortality prediction. Instead, we state that lower creatinine in the present cohorts should be interpreted as part of the broader metabolic and somatic profile of patients with AUD rather than as an isolated renal marker. Discussion: Please clarify the comment regarding the small number of female participants, as females were explicitly excluded. Thank you. We revised the Limitations section to clarify this point. The revised text states that the analysis was restricted to male patients because only eight female patients met the initial screening criteria, which was insufficient for meaningful sex-stratified analysis. Given known sex-related differences in alcohol metabolism, body composition, and biochemical and hematological profiles, women were therefore excluded from the final analytical dataset. We also added that the findings should be interpreted as primarily applicable to male patients with AUD, and that future studies should include adequately powered female cohorts. Discussion: Please clarify the statement regarding low PLT and withdrawal-related neuropsychiatric complications, as the cited paper refers to delirium tremens and withdrawal seizures, and the current paper did not appear to collect these outcomes. The current paper also analyzed blood results categorically and has limited ability to comment on severity of thrombocytopenia. Thank you for this important clarification. We revised this section to avoid overinterpretation. We no longer refer to severe thrombocytopenia as an outcome category. Instead, we provide the platelet findings in relation to the reference range and explicitly state the available clinical data. The revised Discussion now states that thrombocytopenia was observed in patients with AUD. We added median PLT values across cohorts and the proportions of participants with PLT values below the reference range. We also clarified that, although platelet counts below 119,000/μL have been associated with increased risk of withdrawal seizures and delirium tremens in previous research, clinically documented delirium and hallucinations during withdrawal were recorded in only 16 of 292 patients with AUD in our cohort; among them, only one had PLT below the reference range, one had PLT at the lower reference limit, and 14 had values within the reference range. We therefore revised the conclusion to state that reduced PLT was an important hematological feature of AUD but showed no clear correspondence with recorded withdrawal-related delirium or hallucinations in this cohort. Discussion: The statement about combining biochemical, hematological, and physiological markers to enhance diagnostic accuracy needs further context on what is being diagnosed, why diagnostic accuracy may be difficult, and the clinical importance of accurate diagnosis. Thank you. We revised the ROC interpretation in both the Results and Discussion sections. We clarified that two diagnostic comparisons were assessed: first, discrimination between all patients with AUD and alcohol-free controls; second, differentiation between patients with AUD and chronic viral infection and patients with AUD without chronic viral infection. We also clarified that AUROC was used to quantify discriminatory performance and that AUROC values below 0.5 reflected inverse discrimination according to the predefined class coding, rather than necessarily indicating absence of discriminatory value. In the Discussion, we revised the statement to clarify that combined biomarker panels may be more informative than isolated markers for distinguishing AUD from alcohol-free controls and for identifying viral comorbidity within AUD cohorts. We also added clinical context: chronic alcohol exposure and viral infections can produce overlapping hepatic, inflammatory, and metabolic abnormalities, making interpretation of single laboratory parameters difficult. We further clarified that markers with limited discriminatory performance, including platelets, hemoglobin, and BMI, should be interpreted as supportive clinical features rather than standalone diagnostic indicators. Supplementary tables: Within Table S1, please provide a legend with abbreviations written out in full and provide the thresholds defined as normal range. Thank you. Supplementary Table S1 was revised. We added a legend defining hematological abbreviations, including Hb, LYM, MCV, MON, MPV, NEUT, PLT, ESR, and WBC. We also added the specific reference intervals used to define low, normal, and high values. Supplementary tables: Within Table S2, please clarify whether glucose is random or fasted. Thank you. Supplementary Table S2 was revised to clarify glucose sampling. We added that glucose values in the patient group represent random/non-fasting blood glucose measured at admission, whereas blood samples from controls were obtained under fasting conditions. This clarification was also added to the Methods section. Supplementary tables: Consistency in bilirubin labeling would be helpful. Thank you. We harmonized bilirubin terminology throughout the manuscript and supplementary materials. We now use direct (conjugated) bilirubin and indirect (unconjugated) bilirubin consistently where relevant. Dataset: Participant ID and “encrypted name, nation” may contain identifying information. Please consider whether further anonymization is needed. Thank you. We carefully reviewed and revised the dataset. The dataset file deposited in Zenodo was additionally anonymized. Potentially identifying or non-essential fields, including the encrypted name and nationality-related field, were removed. The dataset now retains anonymized participant IDs and the variables required for reproducibility of the analysis. Dataset: The “note” column contains comorbidity information not required for replication and may be identifying if specific dates are included. Please consider removing this column. Thank you. We removed the free-text note column from the dataset to reduce re-identification risk. Comorbidity-related information necessary for the analysis is retained in structured, analyzable variables, while potentially identifying free-text information was removed. Additional data and references During the revision, we also checked the reference list and corrected/replaced several references where needed to ensure that all cited sources accurately support the corresponding statements. The Zenodo repository was updated to include the additionally de-identified underlying dataset and clarified extended data files. No changes were made to study groups, statistical analyses, numerical results, or reported conclusions. We are grateful to the reviewer for the detailed and constructive comments. We believe that the revised version is clearer, more transparent, more cautious in interpretation, and better aligned with the available data and reporting standards. Dear Reviewer, We would like to sincerely thank you for your careful and constructive review of our manuscript. We are grateful for your positive assessment that the study is a helpful addition to the literature on hematological and biochemical biomarkers and comorbidities in individuals with AUD and chronic viral illnesses in Uzbekistan. We also appreciate your detailed suggestions, which helped us improve the clarity, methodological transparency, terminology, interpretation, supplementary materials, and dataset anonymization. We have revised the manuscript carefully in response to all comments. In addition, the supplementary materials and dataset deposited in Zenodo were revised for clarity and further anonymization. No changes were made to the study groups, statistical analyses, numerical results, or reported conclusions. Below we provide a point-by-point response. General comment: Terminology needs to be clear and more consistent when describing cases throughout the paper. The reviewer noted inconsistent use of “stage II chronic alcoholism,” “stage 2 alcohol use disorder,” “mild AUD,” and the term “addicts” in Figure 1. Thank you for this important comment. We revised the terminology throughout the manuscript to improve consistency and to avoid stigmatizing language. The term “addicts” was removed and replaced with person-first terminology. We now consistently refer to the patient groups as “patients with AUD” or “AUD cohorts.” We also clarified that the diagnosis was alcohol use disorder according to ICD-10 code F10.2. The wording suggesting that ICD-10 defines AUD by “stages” was removed or revised. In the Methods section, we now specify that inclusion criteria were male sex, age 20-65 years, inpatient status, and a clinical diagnosis of AUD (ICD-10 F10.2), established by an addiction psychiatrist and supported by AUDIT. We also clarified the exclusion of individuals with mild alcohol-related conditions or clinically mild withdrawal presentations. The revised Methods state that individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. Abstract: The abstract could better orientate the reader by clarifying that the viral infections studied refer to chronic viral infections, such as hepatitis B, hepatitis C, and HIV. Thank you. We revised the Abstract to clarify this point. The Background now states that the study examined biomarker signatures in men with AUD in Uzbekistan, with and without chronic viral infections, specifically hepatitis B, hepatitis C, and HIV. This clarification was also applied throughout the manuscript, including the Methods, Results, Discussion, figure/table legends, and data descriptions. Methodology: Please include the specific dates of the 3-month study period, whether participants were inpatients or outpatients, and how biomarker values were selected if more than one value was available per participant. Thank you. We expanded the Methods section substantially. We now specify that clinical and laboratory data were collected from 19 March to 22 June 2025. We also clarify that patients were recruited from inpatient units of the Republican Specialized Scientific and Practical Medical Center for Mental Health. We added that laboratory measurements were obtained at admission, before treatment initiation, and were considered baseline values. Only admission values were included in the analysis, and follow-up measurements during treatment were excluded. This was added to clarify how biomarker values were selected. Methodology: It is not clear whether controls were selected from patients at the centre or from another group. Thank you for noting this. We clarified the control group source. The revised Methods state that the control group consisted of male volunteers of approximately similar age, including employees of the same institution and relatives of employees. Controls had no history of alcohol use disorder or psychoactive substance use, as confirmed by questionnaire-based screening and clinical assessment. We also clarified that one initially screened control participant was excluded because of a self-reported history of chronic hepatitis B, as the control group was defined to include individuals without known chronic viral infections. Methodology: A brief sentence explaining the De Ritis ratio needs to be included in the Methods section rather than in the Discussion. Thank you. We added a methodological explanation in the Data Collection section. The revised manuscript now states that the De Ritis ratio was calculated as the ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT) and was used to characterize patterns of liver injury. Methodology: Please explain how data on BMI, ethnicity, comorbidities, and alcohol withdrawal symptoms were obtained, and how withdrawal was categorized as mild, moderate, or severe. Thank you. We expanded the Data Collection and Inclusion/Exclusion Criteria sections. The revised Methods now state that data on age, ethnicity, comorbidities, alcohol-use history, alcohol withdrawal symptoms, and clinical status were obtained from medical records, physician assessments, patient interviews, available collateral history, ultrasound reports, and documented diagnoses. Anthropometric data, including height and weight, were collected from medical records and questionnaires, and BMI was calculated as weight in kilograms divided by height in meters squared. We also added a detailed explanation of alcohol withdrawal severity classification. Withdrawal severity was assessed clinically by the treating addiction psychiatrist and classified as mild, moderate, or severe according to the intensity of autonomic, somatic, and neuropsychiatric symptoms, including tremor, agitation, anxiety, sleep disturbance, nausea/vomiting, disorientation, hallucinations, delusional symptoms, and the need for inpatient monitoring or pharmacological management. Mild withdrawal was defined as limited autonomic or anxiety-related symptoms without clinically significant neuropsychiatric manifestations or somatic instability. Moderate withdrawal included more pronounced symptoms requiring inpatient observation and treatment, whereas severe withdrawal was characterized by delirium, hallucinations, delusional symptoms, marked agitation, or clinically significant somatic instability. Methodology: Please comment on whether delusions/hallucinations were related to alcohol withdrawal or could be related to primary mental illness, and how these data were obtained. Thank you. We added a clarification in the Data Collection section. The revised manuscript states that delirium, hallucinations, and delusional symptoms were recorded only when documented by the treating addiction psychiatrist during the withdrawal episode. These data were obtained from clinical examination, patient interview, medical history, available collateral history, and medical record review. We also clarified that symptoms were considered withdrawal-related when they occurred in the context of alcohol withdrawal and were not documented as part of a primary psychiatric disorder. According to the medical records, these patients had no previous registration or documented history of primary psychotic disorders. Methodology: The Methods section states that patients with mild withdrawal symptoms were excluded. Please explain why this decision was made. Thank you. We clarified this point in the Study Design and Population section and in the Inclusion/Exclusion Criteria section. Individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. This was intended to maintain clinical comparability within the analytical cohort. Results: The statement regarding “right shift” in the differential count and its interpretation as suggestive of megaloblastic anemia or hepatic/renal impairment requires further support. Thank you for this very helpful comment. We revised this section to avoid unsupported interpretation. The term “right shift” was removed. We now state that an increased proportion of segmented neutrophils was observed in 7.6–9.8% of patients; however, because direct morphological assessment of neutrophil hypersegmentation was not performed, this finding should be interpreted cautiously and cannot be used to infer megaloblastic anemia or hepatic/renal impairment. This revision ensures that the interpretation remains aligned with the data actually available in the study. Discussion: Please review the Discussion to ensure that claims do not go beyond the data presented or cited. Thank you. We carefully revised the Discussion to make the interpretation more cautious and better aligned with the available data. Several statements were softened or clarified. For example, causal or overly strong wording was revised to more cautious language such as “may reflect,” “may aggravate,” “suggesting a greater likelihood,” and “should be interpreted cautiously.” We also revised the interpretation of neuropsychiatric symptoms, platelet counts, creatinine/MELD, ROC findings, bilirubin findings, and biomarker diagnostic utility to avoid overinterpretation. Discussion: The term “granulocytopenia” is used, but data on eosinophils and basophils are not provided. Please clarify whether this refers specifically to low neutrophils or to low granulocytes. Thank you. We revised this terminology. Because eosinophil and basophil data were not included, we removed the broader term “granulocytopenia” where it could be misleading and clarified the finding as neutropenia/neutrophilic granulocyte compartment suppression. The revised Discussion now states that alcohol-related disruption of granulopoiesis has been described as a mechanism contributing to impaired innate immune defense and increased susceptibility to infection. However, in the present AUD cohorts, neutropenia was rare and comparable between virus-positive and virus-negative patients, suggesting that suppression of the neutrophilic granulocyte compartment was not a prominent hematological feature in these patients. Discussion: The reference to previous research on Candida albicans-specific Th17 cells would benefit from further explanation of its relevance to this work. Thank you. We expanded this part of the Discussion to better explain the relevance of the cited work. The revised text now explains that inflammatory marker abnormalities may reflect not only viral-associated inflammatory burden but also alcohol-related disruption of gut-liver immune signaling. We added that Zeng et al. showed that chronic alcohol exposure is associated with intestinal fungal dysbiosis and increased Candida albicans-specific Th17 responses, with these cells detected in the circulation and liver of patients with alcohol-associated liver disease. We also noted that experimental models showed ethanol-associated migration of Candida albicans-specific Th17 cells from the intestine to the liver, where IL-17-mediated signaling contributed to hepatic inflammation and injury. This explanation was added to clarify why gut-derived microbial/fungal immune pathways may be relevant to systemic and hepatic inflammation in patients with AUD and chronic viral comorbidity. Discussion: The statement that the findings support including creatinine in the MELD score is not adequately supported, as mortality was not explored. Thank you. We agree and revised this section substantially. The unsupported statement was removed. The revised Discussion now states that creatinine was significantly lower in patients with AUD, consistent with prior reports. We explain that, in the context of chronic alcohol exposure, reduced creatinine may reflect lower skeletal muscle mass, malnutrition, or altered protein metabolism rather than preserved renal function. We also clarified that creatinine remains an important component of liver disease severity assessment, including the MELD score, where it is considered together with bilirubin and INR to support risk stratification in advanced liver disease. We no longer imply that our findings validate mortality prediction. Instead, we state that lower creatinine in the present cohorts should be interpreted as part of the broader metabolic and somatic profile of patients with AUD rather than as an isolated renal marker. Discussion: Please clarify the comment regarding the small number of female participants, as females were explicitly excluded. Thank you. We revised the Limitations section to clarify this point. The revised text states that the analysis was restricted to male patients because only eight female patients met the initial screening criteria, which was insufficient for meaningful sex-stratified analysis. Given known sex-related differences in alcohol metabolism, body composition, and biochemical and hematological profiles, women were therefore excluded from the final analytical dataset. We also added that the findings should be interpreted as primarily applicable to male patients with AUD, and that future studies should include adequately powered female cohorts. Discussion: Please clarify the statement regarding low PLT and withdrawal-related neuropsychiatric complications, as the cited paper refers to delirium tremens and withdrawal seizures, and the current paper did not appear to collect these outcomes. The current paper also analyzed blood results categorically and has limited ability to comment on severity of thrombocytopenia. Thank you for this important clarification. We revised this section to avoid overinterpretation. We no longer refer to severe thrombocytopenia as an outcome category. Instead, we provide the platelet findings in relation to the reference range and explicitly state the available clinical data. The revised Discussion now states that thrombocytopenia was observed in patients with AUD. We added median PLT values across cohorts and the proportions of participants with PLT values below the reference range. We also clarified that, although platelet counts below 119,000/μL have been associated with increased risk of withdrawal seizures and delirium tremens in previous research, clinically documented delirium and hallucinations during withdrawal were recorded in only 16 of 292 patients with AUD in our cohort; among them, only one had PLT below the reference range, one had PLT at the lower reference limit, and 14 had values within the reference range. We therefore revised the conclusion to state that reduced PLT was an important hematological feature of AUD but showed no clear correspondence with recorded withdrawal-related delirium or hallucinations in this cohort. Discussion: The statement about combining biochemical, hematological, and physiological markers to enhance diagnostic accuracy needs further context on what is being diagnosed, why diagnostic accuracy may be difficult, and the clinical importance of accurate diagnosis. Thank you. We revised the ROC interpretation in both the Results and Discussion sections. We clarified that two diagnostic comparisons were assessed: first, discrimination between all patients with AUD and alcohol-free controls; second, differentiation between patients with AUD and chronic viral infection and patients with AUD without chronic viral infection. We also clarified that AUROC was used to quantify discriminatory performance and that AUROC values below 0.5 reflected inverse discrimination according to the predefined class coding, rather than necessarily indicating absence of discriminatory value. In the Discussion, we revised the statement to clarify that combined biomarker panels may be more informative than isolated markers for distinguishing AUD from alcohol-free controls and for identifying viral comorbidity within AUD cohorts. We also added clinical context: chronic alcohol exposure and viral infections can produce overlapping hepatic, inflammatory, and metabolic abnormalities, making interpretation of single laboratory parameters difficult. We further clarified that markers with limited discriminatory performance, including platelets, hemoglobin, and BMI, should be interpreted as supportive clinical features rather than standalone diagnostic indicators. Supplementary tables: Within Table S1, please provide a legend with abbreviations written out in full and provide the thresholds defined as normal range. Thank you. Supplementary Table S1 was revised. We added a legend defining hematological abbreviations, including Hb, LYM, MCV, MON, MPV, NEUT, PLT, ESR, and WBC. We also added the specific reference intervals used to define low, normal, and high values. Supplementary tables: Within Table S2, please clarify whether glucose is random or fasted. Thank you. Supplementary Table S2 was revised to clarify glucose sampling. We added that glucose values in the patient group represent random/non-fasting blood glucose measured at admission, whereas blood samples from controls were obtained under fasting conditions. This clarification was also added to the Methods section. Supplementary tables: Consistency in bilirubin labeling would be helpful. Thank you. We harmonized bilirubin terminology throughout the manuscript and supplementary materials. We now use direct (conjugated) bilirubin and indirect (unconjugated) bilirubin consistently where relevant. Dataset: Participant ID and “encrypted name, nation” may contain identifying information. Please consider whether further anonymization is needed. Thank you. We carefully reviewed and revised the dataset. The dataset file deposited in Zenodo was additionally anonymized. Potentially identifying or non-essential fields, including the encrypted name and nationality-related field, were removed. The dataset now retains anonymized participant IDs and the variables required for reproducibility of the analysis. Dataset: The “note” column contains comorbidity information not required for replication and may be identifying if specific dates are included. Please consider removing this column. Thank you. We removed the free-text note column from the dataset to reduce re-identification risk. Comorbidity-related information necessary for the analysis is retained in structured, analyzable variables, while potentially identifying free-text information was removed. Additional data and references During the revision, we also checked the reference list and corrected/replaced several references where needed to ensure that all cited sources accurately support the corresponding statements. The Zenodo repository was updated to include the additionally de-identified underlying dataset and clarified extended data files. No changes were made to study groups, statistical analyses, numerical results, or reported conclusions. We are grateful to the reviewer for the detailed and constructive comments. We believe that the revised version is clearer, more transparent, more cautious in interpretation, and better aligned with the available data and reporting standards. Competing Interests: The authors declare that they have no competing interests. Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 24 Dec 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 Version 2 (revision) 19 May 26 Version 1 24 Dec 25 read Julia Sinclair , University of Southampton, Southampton, UK Julia Morris , University of Southampton, Southampton, UK Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2026 Sinclair J et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 04 Mar 2026 | for Version 1 Julia Sinclair , University of Southampton, Southampton, England, UK Julia Morris , University of Southampton, Southampton, England, UK 0 Views copyright © 2026 Sinclair J et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions General comments: This study is a helpful addition to the literature, in describing haematological and biochemical biomarkers, and comorbidities, in individuals with and without AUD and chronic viral illnesses in Uzbekistan. Terminology needs to be clear and and more consistent when describing cases throughout the paper. For example, within the methodology, cases are described as those with a ‘F10.2 diagnosis of stage II chronic alcoholism’, and later in the paper, ‘stage 2 alcohol use disorder’ . The ICD-10 does not describe AUD as having ‘stages’, so the paper should clarify how cases have been defined (including where the data on diagnostic codes has been obtained from). Relatedly, patients with ‘mild AUD’ are excluded, and so the paper should describe how ‘mild AUD’ has been defined. Additionally, cases are described as ‘addicts’ within Figure 1, which is no longer considered an acceptable term in professional writing to describe individuals with substance use disorders. Abstract: The abstract could better orientate the reader to the purpose of the paper, by clarifying the viral infections studied refer to chronic viral infections (e.g. Hepatitis B, Hepatitis C, HIV) and not typically self-limiting viral infections (e.g. influenza). Methodology: Please include the specific dates of the 3-month study period, whether participants were inpatients or outpatients, and how biomarker values were selected if more than one value was available per participant? Relatedly, it is not clear if controls were selected from patients at the centre or from within another group – this information should be included. A brief sentence explaining the De Ritis ratio needs to be included in the methods section (rather than in the discussion). Please explain how data on participant BMI, ethnicity, comorbidities, and alcohol withdrawal symptoms was obtained, as well as how alcohol withdrawal was categorised as ‘mild’, ‘moderate’ or ‘severe’. Please also comment on whether all delusions/hallucinations referenced in the study are known to be related to alcohol withdrawal, or if these could be related to a primary mental illness, in addition to how this data on specific symptoms was obtained. The methods section states patients with ‘mild withdrawal symptoms’ were excluded. It would be helpful to explain why this decision was made, as it appears (from within the discussion) that patients with both no withdrawal symptoms, and those with severe withdrawal symptoms, were included. Results: Within the results section, a right shift in the differential count is said to be suggestive of megaloblastic anaemia or hepatic/renal impairment. I am not aware ‘right shift’ is a widely accepted term (as ‘left shift’ is) or that this is accepted as suggestive of megaloblastic anaemia or hepatic/renal impairment. Please provide further evidence supporting this statement. Discussion: The authors are encouraged to review their discussion to ensure that they do not make claims beyond the data presented or cited The term ‘granulocytopenia’ is used, however, data on eosinophils and basophils is not provided. Please clarify if this refers specifically to low neutrophils, or to low granulocytes (neutrophils, eosinophils and basophils). The reference to previous research on candida-albicans-specific Th17 cells would benefit from further explanation of its relevance to this work. The statement ‘these findings support including creatinine in the MELD score, a validated mortality predictor in end-stage liver disease’ is not adequately supported by the findings of the paper, as the paper does not explore mortality. Please adjust this statement as it is important not to talk beyond the data Please clarify the comment made regarding the small number of female participants, as females were explicitly excluded. Please clarify the following statement: ‘while low PLT has been associated with withdrawal-related neuropsychiatric complications, no such manifestations were observed in patients with severe thrombocytopenia here’. The paper cited here specifically comments on associations between thrombocytopenia and delirium tremens, and thrombocytopenia and alcohol-withdrawal seizures, when the current paper does not appear to have collected data on either delirium tremens or alcohol-withdrawal seizures. Relatedly, the current paper has analysed blood results categorically (low/normal/high), and therefore has limited ability to comment on the severity of any thrombocytopenia. The statement ‘the findings reinforce the utility of combining biochemical, haematological, and physiological markers to enhance diagnostic accuracy’ does not make sense without further context on what is being diagnosed (e.g. viral infections, AUD), reflection on why diagnostic accuracy may currently be difficult, and the clinical importance of accurate diagnosis. Supplementary tables: Within Table S1, please provide a legend with the abbreviations (e.g. LYM, MON etc.) written out in full. Please also provide the specific thresholds which have been defined as the normal range in the table. Within Table S2, please clarify if the glucose is a random level or fasted. Consistency in bilirubin labelling would be helpful (i.e. direct/indirect or conjugated/unconjugated), as this currently changes throughout the paper and table S2. Dataset: A participant ID is provided, and separately an ‘encrypted name, nation’. The encrypted name looks to very possibly include the patient’s actual initials. Please consider if this needs to be anonymised further, to meet data anonymity requirements. A ‘note’ column contains comorbidity information not required for replication of the study findings, and possibly identifying of individual participants if the recommended changes in the methodology (e.g. including specific dates) are made. Please consider removing this from the table. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Partly If applicable, is the statistical analysis and its interpretation appropriate? Partly Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Partly Competing Interests No competing interests were disclosed. We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 19 May 2026 Natalya Tseomashko, Republican Specialized Scientific and Practical Medical Center for Mental Health, Tashkent, Uzbekistan Dear Reviewer, We would like to sincerely thank you for your careful and constructive review of our manuscript. We are grateful for your positive assessment that the study is a helpful addition to the literature on hematological and biochemical biomarkers and comorbidities in individuals with AUD and chronic viral illnesses in Uzbekistan. We also appreciate your detailed suggestions, which helped us improve the clarity, methodological transparency, terminology, interpretation, supplementary materials, and dataset anonymization. We have revised the manuscript carefully in response to all comments. In addition, the supplementary materials and dataset deposited in Zenodo were revised for clarity and further anonymization. No changes were made to the study groups, statistical analyses, numerical results, or reported conclusions. Below we provide a point-by-point response. General comment: Terminology needs to be clear and more consistent when describing cases throughout the paper. The reviewer noted inconsistent use of “stage II chronic alcoholism,” “stage 2 alcohol use disorder,” “mild AUD,” and the term “addicts” in Figure 1. Thank you for this important comment. We revised the terminology throughout the manuscript to improve consistency and to avoid stigmatizing language. The term “addicts” was removed and replaced with person-first terminology. We now consistently refer to the patient groups as “patients with AUD” or “AUD cohorts.” We also clarified that the diagnosis was alcohol use disorder according to ICD-10 code F10.2. The wording suggesting that ICD-10 defines AUD by “stages” was removed or revised. In the Methods section, we now specify that inclusion criteria were male sex, age 20-65 years, inpatient status, and a clinical diagnosis of AUD (ICD-10 F10.2), established by an addiction psychiatrist and supported by AUDIT. We also clarified the exclusion of individuals with mild alcohol-related conditions or clinically mild withdrawal presentations. The revised Methods state that individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. Abstract: The abstract could better orientate the reader by clarifying that the viral infections studied refer to chronic viral infections, such as hepatitis B, hepatitis C, and HIV. Thank you. We revised the Abstract to clarify this point. The Background now states that the study examined biomarker signatures in men with AUD in Uzbekistan, with and without chronic viral infections, specifically hepatitis B, hepatitis C, and HIV. This clarification was also applied throughout the manuscript, including the Methods, Results, Discussion, figure/table legends, and data descriptions. Methodology: Please include the specific dates of the 3-month study period, whether participants were inpatients or outpatients, and how biomarker values were selected if more than one value was available per participant. Thank you. We expanded the Methods section substantially. We now specify that clinical and laboratory data were collected from 19 March to 22 June 2025. We also clarify that patients were recruited from inpatient units of the Republican Specialized Scientific and Practical Medical Center for Mental Health. We added that laboratory measurements were obtained at admission, before treatment initiation, and were considered baseline values. Only admission values were included in the analysis, and follow-up measurements during treatment were excluded. This was added to clarify how biomarker values were selected. Methodology: It is not clear whether controls were selected from patients at the centre or from another group. Thank you for noting this. We clarified the control group source. The revised Methods state that the control group consisted of male volunteers of approximately similar age, including employees of the same institution and relatives of employees. Controls had no history of alcohol use disorder or psychoactive substance use, as confirmed by questionnaire-based screening and clinical assessment. We also clarified that one initially screened control participant was excluded because of a self-reported history of chronic hepatitis B, as the control group was defined to include individuals without known chronic viral infections. Methodology: A brief sentence explaining the De Ritis ratio needs to be included in the Methods section rather than in the Discussion. Thank you. We added a methodological explanation in the Data Collection section. The revised manuscript now states that the De Ritis ratio was calculated as the ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT) and was used to characterize patterns of liver injury. Methodology: Please explain how data on BMI, ethnicity, comorbidities, and alcohol withdrawal symptoms were obtained, and how withdrawal was categorized as mild, moderate, or severe. Thank you. We expanded the Data Collection and Inclusion/Exclusion Criteria sections. The revised Methods now state that data on age, ethnicity, comorbidities, alcohol-use history, alcohol withdrawal symptoms, and clinical status were obtained from medical records, physician assessments, patient interviews, available collateral history, ultrasound reports, and documented diagnoses. Anthropometric data, including height and weight, were collected from medical records and questionnaires, and BMI was calculated as weight in kilograms divided by height in meters squared. We also added a detailed explanation of alcohol withdrawal severity classification. Withdrawal severity was assessed clinically by the treating addiction psychiatrist and classified as mild, moderate, or severe according to the intensity of autonomic, somatic, and neuropsychiatric symptoms, including tremor, agitation, anxiety, sleep disturbance, nausea/vomiting, disorientation, hallucinations, delusional symptoms, and the need for inpatient monitoring or pharmacological management. Mild withdrawal was defined as limited autonomic or anxiety-related symptoms without clinically significant neuropsychiatric manifestations or somatic instability. Moderate withdrawal included more pronounced symptoms requiring inpatient observation and treatment, whereas severe withdrawal was characterized by delirium, hallucinations, delusional symptoms, marked agitation, or clinically significant somatic instability. Methodology: Please comment on whether delusions/hallucinations were related to alcohol withdrawal or could be related to primary mental illness, and how these data were obtained. Thank you. We added a clarification in the Data Collection section. The revised manuscript states that delirium, hallucinations, and delusional symptoms were recorded only when documented by the treating addiction psychiatrist during the withdrawal episode. These data were obtained from clinical examination, patient interview, medical history, available collateral history, and medical record review. We also clarified that symptoms were considered withdrawal-related when they occurred in the context of alcohol withdrawal and were not documented as part of a primary psychiatric disorder. According to the medical records, these patients had no previous registration or documented history of primary psychotic disorders. Methodology: The Methods section states that patients with mild withdrawal symptoms were excluded. Please explain why this decision was made. Thank you. We clarified this point in the Study Design and Population section and in the Inclusion/Exclusion Criteria section. Individuals with mild alcohol-related conditions (ICD-10 F10.1) or clinically mild withdrawal presentations were excluded because their number was very small and because their short alcohol-use history and clinical profile were not comparable with patients with established long-term AUD. This was intended to maintain clinical comparability within the analytical cohort. Results: The statement regarding “right shift” in the differential count and its interpretation as suggestive of megaloblastic anemia or hepatic/renal impairment requires further support. Thank you for this very helpful comment. We revised this section to avoid unsupported interpretation. The term “right shift” was removed. We now state that an increased proportion of segmented neutrophils was observed in 7.6–9.8% of patients; however, because direct morphological assessment of neutrophil hypersegmentation was not performed, this finding should be interpreted cautiously and cannot be used to infer megaloblastic anemia or hepatic/renal impairment. This revision ensures that the interpretation remains aligned with the data actually available in the study. Discussion: Please review the Discussion to ensure that claims do not go beyond the data presented or cited. Thank you. We carefully revised the Discussion to make the interpretation more cautious and better aligned with the available data. Several statements were softened or clarified. For example, causal or overly strong wording was revised to more cautious language such as “may reflect,” “may aggravate,” “suggesting a greater likelihood,” and “should be interpreted cautiously.” We also revised the interpretation of neuropsychiatric symptoms, platelet counts, creatinine/MELD, ROC findings, bilirubin findings, and biomarker diagnostic utility to avoid overinterpretation. Discussion: The term “granulocytopenia” is used, but data on eosinophils and basophils are not provided. Please clarify whether this refers specifically to low neutrophils or to low granulocytes. Thank you. We revised this terminology. Because eosinophil and basophil data were not included, we removed the broader term “granulocytopenia” where it could be misleading and clarified the finding as neutropenia/neutrophilic granulocyte compartment suppression. The revised Discussion now states that alcohol-related disruption of granulopoiesis has been described as a mechanism contributing to impaired innate immune defense and increased susceptibility to infection. However, in the present AUD cohorts, neutropenia was rare and comparable between virus-positive and virus-negative patients, suggesting that suppression of the neutrophilic granulocyte compartment was not a prominent hematological feature in these patients. Discussion: The reference to previous research on Candida albicans-specific Th17 cells would benefit from further explanation of its relevance to this work. Thank you. We expanded this part of the Discussion to better explain the relevance of the cited work. The revised text now explains that inflammatory marker abnormalities may reflect not only viral-associated inflammatory burden but also alcohol-related disruption of gut-liver immune signaling. We added that Zeng et al. showed that chronic alcohol exposure is associated with intestinal fungal dysbiosis and increased Candida albicans-specific Th17 responses, with these cells detected in the circulation and liver of patients with alcohol-associated liver disease. We also noted that experimental models showed ethanol-associated migration of Candida albicans-specific Th17 cells from the intestine to the liver, where IL-17-mediated signaling contributed to hepatic inflammation and injury. This explanation was added to clarify why gut-derived microbial/fungal immune pathways may be relevant to systemic and hepatic inflammation in patients with AUD and chronic viral comorbidity. Discussion: The statement that the findings support including creatinine in the MELD score is not adequately supported, as mortality was not explored. Thank you. We agree and revised this section substantially. The unsupported statement was removed. The revised Discussion now states that creatinine was significantly lower in patients with AUD, consistent with prior reports. We explain that, in the context of chronic alcohol exposure, reduced creatinine may reflect lower skeletal muscle mass, malnutrition, or altered protein metabolism rather than preserved renal function. We also clarified that creatinine remains an important component of liver disease severity assessment, including the MELD score, where it is considered together with bilirubin and INR to support risk stratification in advanced liver disease. We no longer imply that our findings validate mortality prediction. Instead, we state that lower creatinine in the present cohorts should be interpreted as part of the broader metabolic and somatic profile of patients with AUD rather than as an isolated renal marker. Discussion: Please clarify the comment regarding the small number of female participants, as females were explicitly excluded. Thank you. We revised the Limitations section to clarify this point. The revised text states that the analysis was restricted to male patients because only eight female patients met the initial screening criteria, which was insufficient for meaningful sex-stratified analysis. Given known sex-related differences in alcohol metabolism, body composition, and biochemical and hematological profiles, women were therefore excluded from the final analytical dataset. We also added that the findings should be interpreted as primarily applicable to male patients with AUD, and that future studies should include adequately powered female cohorts. Discussion: Please clarify the statement regarding low PLT and withdrawal-related neuropsychiatric complications, as the cited paper refers to delirium tremens and withdrawal seizures, and the current paper did not appear to collect these outcomes. The current paper also analyzed blood results categorically and has limited ability to comment on severity of thrombocytopenia. Thank you for this important clarification. We revised this section to avoid overinterpretation. We no longer refer to severe thrombocytopenia as an outcome category. Instead, we provide the platelet findings in relation to the reference range and explicitly state the available clinical data. The revised Discussion now states that thrombocytopenia was observed in patients with AUD. We added median PLT values across cohorts and the proportions of participants with PLT values below the reference range. We also clarified that, although platelet counts below 119,000/μL have been associated with increased risk of withdrawal seizures and delirium tremens in previous research, clinically documented delirium and hallucinations during withdrawal were recorded in only 16 of 292 patients with AUD in our cohort; among them, only one had PLT below the reference range, one had PLT at the lower reference limit, and 14 had values within the reference range. We therefore revised the conclusion to state that reduced PLT was an important hematological feature of AUD but showed no clear correspondence with recorded withdrawal-related delirium or hallucinations in this cohort. Discussion: The statement about combining biochemical, hematological, and physiological markers to enhance diagnostic accuracy needs further context on what is being diagnosed, why diagnostic accuracy may be difficult, and the clinical importance of accurate diagnosis. Thank you. We revised the ROC interpretation in both the Results and Discussion sections. We clarified that two diagnostic comparisons were assessed: first, discrimination between all patients with AUD and alcohol-free controls; second, differentiation between patients with AUD and chronic viral infection and patients with AUD without chronic viral infection. We also clarified that AUROC was used to quantify discriminatory performance and that AUROC values below 0.5 reflected inverse discrimination according to the predefined class coding, rather than necessarily indicating absence of discriminatory value. In the Discussion, we revised the statement to clarify that combined biomarker panels may be more informative than isolated markers for distinguishing AUD from alcohol-free controls and for identifying viral comorbidity within AUD cohorts. We also added clinical context: chronic alcohol exposure and viral infections can produce overlapping hepatic, inflammatory, and metabolic abnormalities, making interpretation of single laboratory parameters difficult. We further clarified that markers with limited discriminatory performance, including platelets, hemoglobin, and BMI, should be interpreted as supportive clinical features rather than standalone diagnostic indicators. Supplementary tables: Within Table S1, please provide a legend with abbreviations written out in full and provide the thresholds defined as normal range. Thank you. Supplementary Table S1 was revised. We added a legend defining hematological abbreviations, including Hb, LYM, MCV, MON, MPV, NEUT, PLT, ESR, and WBC. We also added the specific reference intervals used to define low, normal, and high values. Supplementary tables: Within Table S2, please clarify whether glucose is random or fasted. Thank you. Supplementary Table S2 was revised to clarify glucose sampling. We added that glucose values in the patient group represent random/non-fasting blood glucose measured at admission, whereas blood samples from controls were obtained under fasting conditions. This clarification was also added to the Methods section. Supplementary tables: Consistency in bilirubin labeling would be helpful. Thank you. We harmonized bilirubin terminology throughout the manuscript and supplementary materials. We now use direct (conjugated) bilirubin and indirect (unconjugated) bilirubin consistently where relevant. Dataset: Participant ID and “encrypted name, nation” may contain identifying information. Please consider whether further anonymization is needed. Thank you. We carefully reviewed and revised the dataset. The dataset file deposited in Zenodo was additionally anonymized. Potentially identifying or non-essential fields, including the encrypted name and nationality-related field, were removed. The dataset now retains anonymized participant IDs and the variables required for reproducibility of the analysis. Dataset: The “note” column contains comorbidity information not required for replication and may be identifying if specific dates are included. Please consider removing this column. Thank you. We removed the free-text note column from the dataset to reduce re-identification risk. Comorbidity-related information necessary for the analysis is retained in structured, analyzable variables, while potentially identifying free-text information was removed. Additional data and references During the revision, we also checked the reference list and corrected/replaced several references where needed to ensure that all cited sources accurately support the corresponding statements. The Zenodo repository was updated to include the additionally de-identified underlying dataset and clarified extended data files. No changes were made to study groups, statistical analyses, numerical results, or reported conclusions. We are grateful to the reviewer for the detailed and constructive comments. We believe that the revised version is clearer, more transparent, more cautious in interpretation, and better aligned with the available data and reporting standards. View more View less Competing Interests The authors declare that they have no competing interests. reply Respond Report a concern Sinclair J and Morris J. Peer Review Report For: Population-Specific Biomarker Signatures in Alcohol Use Disorder: Ethnic and Viral Influences in a Central Asian Cohort [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1449 ( https://doi.org/) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/14-1449/v1#referee-response-464369 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = \"Population-Specific Biomarker Signatures...\".replace(\"'\", ''); var linkedInUrl = \"http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/14-1449/v1\" + \"&title=\" + encodeURIComponent(lTitle) + \"&summary=\" + encodeURIComponent('Read the article by '); var deliciousUrl = \"https://del.icio.us/post?url=https://f1000research.com/articles/14-1449/v1&title=\" + encodeURIComponent(lTitle); var redditUrl = \"http://reddit.com/submit?url=https://f1000research.com/articles/14-1449/v1\" + \"&title=\" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Tseomashko N et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : \"facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com\", services_expanded : \"facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com\", services_custom : [ { name: \"LinkedIn\", url: linkedInUrl, icon:\"/img/icon/at_linkedin.svg\" }, { name: \"Mendeley\", url: \"http://www.mendeley.com/import/?url=https://f1000research.com/articles/14-1449/v1/mendeley\", icon:\"/img/icon/at_mendeley.svg\" }, { name: \"Reddit\", url: redditUrl, icon:\"/img/icon/at_reddit.svg\" }, ] }; var addthis_share = { url: \"https://f1000research.com/articles/14-1449\", templates : { twitter : \"Population-Specific Biomarker Signatures in Alcohol Use Disorder:.... Tseomashko N et al., published by \" + \"@F1000Research\" + \", https://f1000research.com/articles/14-1449/v1\" } }; if (typeof(addthis) != \"undefined\"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(\".f1r-shares-twitter\").attr(\"href\", \"https://twitter.com/intent/tweet?text=\" + addthis_share.templates.twitter); $(\".f1r-shares-facebook\").attr(\"href\", \"https://www.facebook.com/sharer/sharer.php?u=\" + addthis_share.url); $(\".f1r-shares-linkedin\").attr(\"href\", addthis_config.services_custom[0].url); $(\".f1r-shares-reddit\").attr(\"href\", addthis_config.services_custom[2].url); $(\".f1r-shares-mendelay\").attr(\"href\", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(\".addthis_button_expanded\").each(function(){ var count = $(this).text(); if (count !== \"\" && count != \"0\") $(this).removeClass(\"is-hidden\"); else $(this).addClass(\"is-hidden\"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get(\"/articles/acj/172858/190619\") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay(\"articles\", \"article\", \"190619\"); $(document).ready(function() { $( \"#frame1\" ).on('load', function() { var mydiv = $(this).contents().find(\"div\"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(\".interactive-living-figure-label .icon-more-info\"), titleLivingFigure = tooltipLivingFigure.attr(\"title\"); tooltipLivingFigure.simpletip({ fixed: true, position: [\"-115\", \"30\"], baseClass: 'small-tooltip', content:titleLivingFigure + \" \" }); tooltipLivingFigure.removeAttr(\"title\"); $(\"body\").on(\"click\", \".cite-living-figure\", function(e) { e.preventDefault(); var ref = $(this).attr(\"data-ref\"); $(this).closest(\".living-figure-list-container\").find(\"#\" + ref).fadeIn(200); }); $(\"body\").on(\"click\", \".close-cite-living-figure\", function(e) { e.preventDefault(); $(this).closest(\".popup-window-wrapper\").fadeOut(200); }); $(document).on(\"mouseup\", function(e) { var metricsContainer = $(\".article-metrics-popover-wrapper\"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(\".article-metrics-close-button\").click(); } }); var articleId = $('#articleId').val(); if($(\"#main-article-count-box\").attachArticleMetrics) { $(\"#main-article-count-box\").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(\".new_figshare_widget\"); if (figshareWidget.length > 0) { window.figshare.load(\"f1000\", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr(\"figshare_articleId\") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { \"456838\": 0, \"456839\": 0, \"456836\": 0, \"456837\": 0, \"456834\": 0, \"456835\": 0, \"456833\": 0, \"486413\": 0, \"456842\": 0, \"456840\": 0, \"456841\": 0, \"453654\": 0, \"453655\": 0, \"453652\": 0, \"453653\": 0, \"453650\": 0, \"453651\": 0, \"453658\": 0, \"453659\": 0, \"453656\": 0, \"453657\": 0, \"461239\": 0, \"446262\": 0, \"461238\": 0, \"446263\": 0, \"461237\": 0, \"446260\": 0, \"461236\": 0, \"446261\": 0, \"461235\": 0, \"446258\": 0, \"461234\": 0, \"446259\": 0, \"446257\": 0, \"486975\": 0, \"448574\": 0, \"486974\": 0, \"448575\": 0, \"486973\": 0, \"448572\": 0, \"486972\": 0, \"448573\": 0, \"486971\": 0, \"461243\": 0, \"446266\": 0, \"448570\": 0, \"486970\": 0, \"461242\": 0, \"448571\": 0, \"486969\": 0, \"461241\": 0, \"446264\": 0, \"461240\": 0, \"446265\": 0, \"448569\": 0, \"486979\": 0, \"448578\": 0, \"486978\": 0, \"486977\": 0, \"448576\": 0, \"486976\": 0, \"448577\": 0, \"464369\": 17, }; $(\".referee-response-container,.js-referee-report\").each(function(index, el) { var reportId = $(el).attr(\"data-reportid\"), reportCount = reportIds[reportId] || 0; $(el).find(\".comments-count-container,.js-referee-report-views\").html(reportCount); }); var uuidInput = $(\"#article_uuid\"), oldUUId = uuidInput.val(), newUUId = \"f295c456-7a27-4189-b72c-f82a7c775a8b\"; uuidInput.val(newUUId); $(\"a[href*='article_uuid=']\").each(function(index, el) { var newHref = $(el).attr(\"href\").replace(oldUUId, newUUId); $(el).attr(\"href\", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: \"f1000research\", displayName: \"F1000Research\", hostName: \"f1000research.com\", id: \"1\", editorialEmail: \"research@f1000.com\", infoEmail: \"info@f1000.com\", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(\".cookie-warning\").is(\":visible\")) { $(\".sticky\").css(\"margin-bottom\", \"35px\"); $(\".devices\").addClass(\"devices-and-cookie-warning\"); } $(\".cookie-warning .close-button\").click(function (e) { $(\".devices\").removeClass(\"devices-and-cookie-warning\"); $(\".sticky\").css(\"margin-bottom\", \"0\"); }); $(\"#tweeter-feed .tweet-message\").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(\".partner\").on(\"mouseenter mouseleave\", function() { $(this).find(\".gray-scale, .colour\").toggleClass(\"is-hidden\"); }); }); <!-- Sign in --> Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $(\"a[id=googleSignInButton]\").click(function(event){ event.preventDefault(); $(\"input[id=oAuthSystem]\").val(\"GOOGLE\"); $(\"form[id=oAuthForm]\").submit(); }); $(\"a[id=facebookSignInButton]\").click(function(event){ event.preventDefault(); $(\"input[id=oAuthSystem]\").val(\"FACEBOOK\"); $(\"form[id=oAuthForm]\").submit(); }); $(\"a[id=orcidSignInButton]\").click(function(event){ event.preventDefault(); $(\"input[id=oAuthSystem]\").val(\"ORCID\"); $(\"form[id=oAuthForm]\").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($(\"#sign-in-form-gfb-popup\")); $(\".target-field\").each(function () { var uris = $(this).val().split(\"/\"); if (uris.pop() === \"login\") { $(this).val(uris.toString().replace(\",\",\"/\")); } }); });","source_license":"CC-BY-4.0","license_restricted":false}